CA2292900A1 - Live attenuated vaccines - Google Patents
Live attenuated vaccines Download PDFInfo
- Publication number
- CA2292900A1 CA2292900A1 CA002292900A CA2292900A CA2292900A1 CA 2292900 A1 CA2292900 A1 CA 2292900A1 CA 002292900 A CA002292900 A CA 002292900A CA 2292900 A CA2292900 A CA 2292900A CA 2292900 A1 CA2292900 A1 CA 2292900A1
- Authority
- CA
- Canada
- Prior art keywords
- gene
- bacterium
- mutation
- fur
- attenuated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940124590 live attenuated vaccine Drugs 0.000 title description 15
- 229940023012 live-attenuated vaccine Drugs 0.000 title description 15
- 241000894006 Bacteria Species 0.000 claims abstract description 129
- 229960005486 vaccine Drugs 0.000 claims abstract description 79
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 67
- 230000002238 attenuated effect Effects 0.000 claims abstract description 46
- 230000014509 gene expression Effects 0.000 claims abstract description 43
- 101150046339 fur gene Proteins 0.000 claims abstract description 34
- 229910052742 iron Inorganic materials 0.000 claims abstract description 33
- 230000001105 regulatory effect Effects 0.000 claims abstract description 24
- 241000588650 Neisseria meningitidis Species 0.000 claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 188
- 230000035772 mutation Effects 0.000 claims description 108
- 102000004169 proteins and genes Human genes 0.000 claims description 55
- 201000009906 Meningitis Diseases 0.000 claims description 43
- 101150090235 aroB gene Proteins 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 38
- 101150079601 recA gene Proteins 0.000 claims description 36
- 238000004519 manufacturing process Methods 0.000 claims description 35
- 239000012528 membrane Substances 0.000 claims description 27
- 241000588724 Escherichia coli Species 0.000 claims description 23
- 101150002054 galE gene Proteins 0.000 claims description 23
- 108700012359 toxins Proteins 0.000 claims description 20
- 230000004927 fusion Effects 0.000 claims description 18
- 230000012010 growth Effects 0.000 claims description 17
- 241000588653 Neisseria Species 0.000 claims description 12
- 101150007004 aroL gene Proteins 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 11
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 9
- 101150037081 aroA gene Proteins 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000033228 biological regulation Effects 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 101100435931 Methanosarcina acetivorans (strain ATCC 35395 / DSM 2834 / JCM 12185 / C2A) aroK gene Proteins 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 6
- 241001167018 Aroa Species 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 5
- 101100491986 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) aromA gene Proteins 0.000 claims description 5
- 101150042732 aroC gene Proteins 0.000 claims description 5
- 101150102858 aroD gene Proteins 0.000 claims description 5
- 101150040872 aroE gene Proteins 0.000 claims description 5
- 239000002207 metabolite Substances 0.000 claims description 5
- 101150098691 pyrB gene Proteins 0.000 claims description 5
- 101100354953 Treponema denticola (strain ATCC 35405 / DSM 14222 / CIP 103919 / JCM 8153 / KCTC 15104) pyrBI gene Proteins 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 101100523058 Aspergillus niger pyrG gene Proteins 0.000 claims description 3
- 101100216993 Bacillus subtilis (strain 168) aroD gene Proteins 0.000 claims description 3
- 206010010071 Coma Diseases 0.000 claims description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 3
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims description 3
- 241000607768 Shigella Species 0.000 claims description 3
- 241000607626 Vibrio cholerae Species 0.000 claims description 3
- 101150108612 aroQ gene Proteins 0.000 claims description 3
- 101150014229 carA gene Proteins 0.000 claims description 3
- 101150070764 carB gene Proteins 0.000 claims description 3
- 230000000688 enterotoxigenic effect Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 241000588832 Bordetella pertussis Species 0.000 claims description 2
- 241000606768 Haemophilus influenzae Species 0.000 claims description 2
- 241000590002 Helicobacter pylori Species 0.000 claims description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000000369 enteropathogenic effect Effects 0.000 claims description 2
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 2
- 229940037467 helicobacter pylori Drugs 0.000 claims description 2
- 229940118696 vibrio cholerae Drugs 0.000 claims description 2
- 101150002764 purA gene Proteins 0.000 claims 1
- 101150044726 pyrE gene Proteins 0.000 claims 1
- 239000013598 vector Substances 0.000 description 26
- 238000012217 deletion Methods 0.000 description 25
- 230000037430 deletion Effects 0.000 description 25
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 108091007433 antigens Proteins 0.000 description 19
- 102000036639 antigens Human genes 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 18
- 239000012634 fragment Substances 0.000 description 17
- 239000000427 antigen Substances 0.000 description 16
- 239000003053 toxin Substances 0.000 description 16
- 230000004224 protection Effects 0.000 description 15
- 231100000765 toxin Toxicity 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 14
- 230000037361 pathway Effects 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 12
- 238000010276 construction Methods 0.000 description 11
- 229960003276 erythromycin Drugs 0.000 description 11
- 230000002068 genetic effect Effects 0.000 description 11
- 230000028993 immune response Effects 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 239000003550 marker Substances 0.000 description 11
- 101000787195 Escherichia coli (strain K12) Aldose sugar dehydrogenase YliI Proteins 0.000 description 10
- 101000728677 Pseudomonas sp Bifunctional aspartate aminotransferase and L-aspartate beta-decarboxylase Proteins 0.000 description 10
- 238000002744 homologous recombination Methods 0.000 description 10
- 230000006801 homologous recombination Effects 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 230000001717 pathogenic effect Effects 0.000 description 9
- 229960005322 streptomycin Drugs 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 8
- 230000006798 recombination Effects 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 101710116435 Outer membrane protein Proteins 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 7
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 7
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 6
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 6
- 235000020774 essential nutrients Nutrition 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 5
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 5
- 101150100857 RIOX2 gene Proteins 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- -1 aromatic amino acid Chemical class 0.000 description 5
- 101150107204 asd gene Proteins 0.000 description 5
- 229960005091 chloramphenicol Drugs 0.000 description 5
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000000415 inactivating effect Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 102000018120 Recombinases Human genes 0.000 description 4
- 108010091086 Recombinases Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000003850 cellular structure Anatomy 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229910001447 ferric ion Inorganic materials 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 210000001989 nasopharynx Anatomy 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 108700039887 Essential Genes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101710169972 Menin Proteins 0.000 description 3
- 102100030550 Menin Human genes 0.000 description 3
- 206010073261 Ovarian theca cell tumour Diseases 0.000 description 3
- 201000005702 Pertussis Diseases 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001851 biosynthetic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000007667 floating Methods 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 101150066555 lacZ gene Proteins 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 108010009004 proteose-peptone Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 208000001644 thecoma Diseases 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- QYOJSKGCWNAKGW-PBXRRBTRSA-N 3-phosphoshikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](OP(O)(O)=O)[C@H]1O QYOJSKGCWNAKGW-PBXRRBTRSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000700201 Galea Species 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101100301240 Myxococcus xanthus recA2 gene Proteins 0.000 description 2
- 241001440871 Neisseria sp. Species 0.000 description 2
- 241001212279 Neisseriales Species 0.000 description 2
- 101100491995 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aro-1 gene Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 241000831652 Salinivibrio sharmensis Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 108050008280 Shikimate dehydrogenase Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 101150083869 aroK gene Proteins 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- 230000001925 catabolic effect Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 101150029207 frpA gene Proteins 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 101150105522 parA gene Proteins 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 101150020633 tbp-1 gene Proteins 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 244000000057 wild-type pathogen Species 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- WTFXTQVDAKGDEY-UHFFFAOYSA-N (-)-chorismic acid Natural products OC1C=CC(C(O)=O)=CC1OC(=C)C(O)=O WTFXTQVDAKGDEY-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- 108010038550 3-dehydroquinate dehydratase Proteins 0.000 description 1
- 108050006180 3-dehydroquinate synthase Proteins 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 102000055161 Adenylosuccinate lyases Human genes 0.000 description 1
- 101100163490 Alkalihalobacillus halodurans (strain ATCC BAA-125 / DSM 18197 / FERM 7344 / JCM 9153 / C-125) aroA1 gene Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 102000030907 Aspartate Carbamoyltransferase Human genes 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108700003860 Bacterial Genes Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010003662 Chorismate synthase Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 101000728671 Comamonas testosteroni Bifunctional aspartate aminotransferase and L-aspartate beta-decarboxylase Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108091000126 Dihydroorotase Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108010000916 Fimbriae Proteins Proteins 0.000 description 1
- 206010056663 Gastric infection Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 101001131930 Homo sapiens Transcriptional activator protein Pur-beta Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 206010027249 Meningitis meningococcal Diseases 0.000 description 1
- 201000010924 Meningococcal meningitis Diseases 0.000 description 1
- 241000717981 Meringis Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 101100324192 Neisseria gonorrhoeae aroB gene Proteins 0.000 description 1
- 101100216944 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aro-2 gene Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108010055016 Rec A Recombinases Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 101710117021 Tyrosine-protein phosphatase YopH Proteins 0.000 description 1
- 102100021436 UDP-glucose 4-epimerase Human genes 0.000 description 1
- 108010075202 UDP-glucose 4-epimerase Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 210000003578 bacterial chromosome Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- WTFXTQVDAKGDEY-HTQZYQBOSA-N chorismic acid Chemical compound O[C@@H]1C=CC(C(O)=O)=C[C@H]1OC(=C)C(O)=O WTFXTQVDAKGDEY-HTQZYQBOSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 101150098857 comA gene Proteins 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 101150116335 isdA gene Proteins 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 150000002597 lactoses Chemical class 0.000 description 1
- 238000013493 large scale plasmid preparation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012577 media supplement Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940079938 nitrocellulose Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000030788 protein refolding Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 101150085681 purB gene Proteins 0.000 description 1
- 101150019467 purE gene Proteins 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 101150019517 pyrAB gene Proteins 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 101150007503 rps1 gene Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- TXBNDGDMWKVRQW-UHFFFAOYSA-M sodium;2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]acetate;dodecyl sulfate Chemical compound [Na+].OCC(CO)(CO)NCC(O)=O.CCCCCCCCCCCCOS([O-])(=O)=O TXBNDGDMWKVRQW-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229960004319 trichloroacetic acid Drugs 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
An attenuated bacterium in which the native fur gene, or homologue thereof, is modified such that the expression of the fur gene product, or homologue thereof, is regulated independently of the iron concentration in the environment of the bacterium, is suitable for use as a live vaccine. The bacterium may be, in particular, Neisseria meningitidis.
Description
LIVE ATTENUATED VACCINES
Field of the Invention The present invention relates to attenuated strains of pathogenic bacteria, particularly of Neisseria meningitides. These strains are particularly useful as live attenuated vaccines.
Background to the Invention Bacterial infections are a significant cause of disease throughout the world.
Many bacterial infections can prove fatal, particularly in vulnerable individuals such as infants, children, the elderly or those who are immunocompromised by other diseases or through injury.
Bacterial diseases which are still prevalent include meningococcal meningitis, caused by Neisseria meningitides and gonorrhoea, caused by the related organism Neisseria gonorrhoeae.
Both these organisms are gram-negative bacteria. Other gram-negative bacteria include Helicobacter pylori (associated with stomach ulcers), Salmonella spp., e.g.
Salmonella typhi or Salmonella typhimurium, enteropathogenic E. coli (EPEC), enteroinvasive E.
coli (EIEC), enterotoxigenic E. coli (ETEC), enterohaemorrhagic E. coli (EHEC), verotoxigenic E. coli (VTEC), Vibrio cholerae, Shigella spp., (all of which cause gastric infections), Haemophilus influenzae and Bordetella pertussis, which may cause meningitis and whooping cough respectively, particularly in children, and Pseudomonas aeruginosa, which can cause infection in infants, children and adults and is particularly a problem in individuals who have cystic fibrosis.
The goal of any vaccine development programme is to provide a vaccine which is safe, capable of providing cross-group protection and capable of providing long-term protection.
Traditionally there are three main groups of vaccine types. (1) Killed vaccines, where the killed pathogen is used directly, (2) Defined vaccines where purified components of the pathogen are used and (3) Live attenuated vaccines, where the live pathogen is used which has been rendered unable to grow for extended periods in the host. Each of these vaccine types presents different advantages and disadvantages.
Killed vaccines are superficially attractive, particularly from the safety point of view.
However such vaccines can not proliferate or colonise, nor is there any dynamic gene expression, which might result in the production of useful antigens which elicit an immunoprotective response. Indeed the production of the killed vaccine usually results in the
Field of the Invention The present invention relates to attenuated strains of pathogenic bacteria, particularly of Neisseria meningitides. These strains are particularly useful as live attenuated vaccines.
Background to the Invention Bacterial infections are a significant cause of disease throughout the world.
Many bacterial infections can prove fatal, particularly in vulnerable individuals such as infants, children, the elderly or those who are immunocompromised by other diseases or through injury.
Bacterial diseases which are still prevalent include meningococcal meningitis, caused by Neisseria meningitides and gonorrhoea, caused by the related organism Neisseria gonorrhoeae.
Both these organisms are gram-negative bacteria. Other gram-negative bacteria include Helicobacter pylori (associated with stomach ulcers), Salmonella spp., e.g.
Salmonella typhi or Salmonella typhimurium, enteropathogenic E. coli (EPEC), enteroinvasive E.
coli (EIEC), enterotoxigenic E. coli (ETEC), enterohaemorrhagic E. coli (EHEC), verotoxigenic E. coli (VTEC), Vibrio cholerae, Shigella spp., (all of which cause gastric infections), Haemophilus influenzae and Bordetella pertussis, which may cause meningitis and whooping cough respectively, particularly in children, and Pseudomonas aeruginosa, which can cause infection in infants, children and adults and is particularly a problem in individuals who have cystic fibrosis.
The goal of any vaccine development programme is to provide a vaccine which is safe, capable of providing cross-group protection and capable of providing long-term protection.
Traditionally there are three main groups of vaccine types. (1) Killed vaccines, where the killed pathogen is used directly, (2) Defined vaccines where purified components of the pathogen are used and (3) Live attenuated vaccines, where the live pathogen is used which has been rendered unable to grow for extended periods in the host. Each of these vaccine types presents different advantages and disadvantages.
Killed vaccines are superficially attractive, particularly from the safety point of view.
However such vaccines can not proliferate or colonise, nor is there any dynamic gene expression, which might result in the production of useful antigens which elicit an immunoprotective response. Indeed the production of the killed vaccine usually results in the
-2-exposure of internal antigens such as lipid A which may compromise its use due to induction of adverse reactions in the host. In most cases the causes) of these deleterious effects are unknown.
In view of such problems, many researchers have endorsed a defined or subunit vaccine approach where those antigens which appear to elicit the "best immune response" in the host are purified and used directly as a vaccine. This approach again avoids the use of live bacteria which is also attractive from the safety and regulatory point of view. The chosen components may be subunits of actual virulence proteins or somatic proteins. There are obvious advantages to this approach:- (1 ) The vaccine is totally defined and the immunogenicity of each purified component protein is understood. (2) Any toxic component which may elicit adverse effects can be eliminated from the vaccine. (3) If the same strain and procedures are used there is the potential for vaccines made in different locations being consistent. (4) Since the vaccine is composed of purified cell components, it is likely to be relatively stable under normal conditions of storage.
There are also major disadvantages to this approach. ( 1 ) Only selected cell components are used and these may not on their own be sufficient to elicit good protective long term immunity. {2) The most important antigens for full protection may be unidentified and/or only be expressed under in vivo conditions and therefore will be absent from the vaccine. (3) Vaccine production entails expensive protein and/or cell component purifications reliant on advanced technology. (4) Protein antigens most important for the host immune response will most probably be secreted toxins or surface exposed outer membrane proteins which may undergo some degree of denaturation during purification. Denatured proteins will lose conformational epitopes that may be important and if used in vaccines may elicit immune responses to epitopes which are not present in the native, membrane associated protein. (5) Purified outer membrane proteins may require an additional, expensive renaturation step, and possibly re-insertion into a membrane vesicle carrier to make them useful as a vaccine.
(6) Renaturation of proteins in vitro is difficult and never completely successful. Aberrant epitopes may remain and the important epitopes of the protein not be reformed even when inserted into membrane vesicles. Therefore it is probably naive to expect that a few proteins purified apart from their normal membrane environment would elicit a good cell mediated response in the host. (7) Association of individual outer membrane proteins in the membrane surface of the intact organism appears important for the induction of an immune response to the
In view of such problems, many researchers have endorsed a defined or subunit vaccine approach where those antigens which appear to elicit the "best immune response" in the host are purified and used directly as a vaccine. This approach again avoids the use of live bacteria which is also attractive from the safety and regulatory point of view. The chosen components may be subunits of actual virulence proteins or somatic proteins. There are obvious advantages to this approach:- (1 ) The vaccine is totally defined and the immunogenicity of each purified component protein is understood. (2) Any toxic component which may elicit adverse effects can be eliminated from the vaccine. (3) If the same strain and procedures are used there is the potential for vaccines made in different locations being consistent. (4) Since the vaccine is composed of purified cell components, it is likely to be relatively stable under normal conditions of storage.
There are also major disadvantages to this approach. ( 1 ) Only selected cell components are used and these may not on their own be sufficient to elicit good protective long term immunity. {2) The most important antigens for full protection may be unidentified and/or only be expressed under in vivo conditions and therefore will be absent from the vaccine. (3) Vaccine production entails expensive protein and/or cell component purifications reliant on advanced technology. (4) Protein antigens most important for the host immune response will most probably be secreted toxins or surface exposed outer membrane proteins which may undergo some degree of denaturation during purification. Denatured proteins will lose conformational epitopes that may be important and if used in vaccines may elicit immune responses to epitopes which are not present in the native, membrane associated protein. (5) Purified outer membrane proteins may require an additional, expensive renaturation step, and possibly re-insertion into a membrane vesicle carrier to make them useful as a vaccine.
(6) Renaturation of proteins in vitro is difficult and never completely successful. Aberrant epitopes may remain and the important epitopes of the protein not be reformed even when inserted into membrane vesicles. Therefore it is probably naive to expect that a few proteins purified apart from their normal membrane environment would elicit a good cell mediated response in the host. (7) Association of individual outer membrane proteins in the membrane surface of the intact organism appears important for the induction of an immune response to the
-3-individual proteins. Proteins removed from such associations may not elicit protective/bactericidal responses even though they may do so in the intact organism. This may be due to conformational epitopes being formed between two or more associated proteins. (8) The normal association of proteins within the membrane may generate important antigenic epitopes which could be lost when individual components are purified. Thus in many respects, defined/subunit vaccines are far from ideal.
Live attenuated vaccines offer the best prospect for a vaccine which will give similar protection to that seen with the natural disease. The advantages of a live attenuated vaccine are numerous. ( 1 ) The whole live organism is used, rather than dead cells or selected cell components which may exhibit modified or denatured antigens. Therefore the potential to elicit a good protective long term immunity should be higher. (2) The most important antigens for full protection need not be identified, since the vaccine will only have specific modifications for attenuation it will still be able to express these important antigens under in vivo conditions. (3) Production costs should be a fraction of more intensive and expensive vaccine production procedures, since there is no protein/subunit purification, protein refolding, or down stream processing required except the minimum essential for the vaccine application.
Live attenuated vaccines offer the best prospect for a vaccine which will give similar protection to that seen with the natural disease. The advantages of a live attenuated vaccine are numerous. ( 1 ) The whole live organism is used, rather than dead cells or selected cell components which may exhibit modified or denatured antigens. Therefore the potential to elicit a good protective long term immunity should be higher. (2) The most important antigens for full protection need not be identified, since the vaccine will only have specific modifications for attenuation it will still be able to express these important antigens under in vivo conditions. (3) Production costs should be a fraction of more intensive and expensive vaccine production procedures, since there is no protein/subunit purification, protein refolding, or down stream processing required except the minimum essential for the vaccine application.
(4) Protein antigens in the outer membrane will maintain their tertiary and quaternary structures. (5) The associations between individual proteins in the membrane surface of the vaccine strain which may be important for the generation of conformational epitopes between two or more associated proteins will be maintained. (6) The fluid structures of these proteins will also be maintained in the attenuated vaccine strain. (7) Since the vaccine is live it will display dynamic gene expression in response to environmental changes and express those proteins which are only present or enhanced in vivo in the wild type pathogen. (8) The host responses to the attenuated strain would mimic that expected for the pathogen since the attenuation process would not affect the expression of the important immunogenic proteins. (9) Production of live attenuated vaccines is much simpler. As long as recommended growth conditions are adhered to and a standard stock of the vaccine strain is maintained and used as the initial inoculum vaccines should be uniform in composition and efficacy. (10) With improved methods of freeze drying and storage the vaccine should be stable and viable at normal ambient temperatures. (11) Live attenuated vaccines can in addition, be important vehicles for the delivery of other antigens/immunogens for example toxins. This would be particularly important where the immunogen which confers complete protection is a secreted toxin, e.g.
diphtheria toxin, ~~~,,;.,. .., w~, .b, EMGFG,~EPA-Munchen 05 ;11- 8-99 ; 18.58 ~ 0171 242 8°22-' ~~ 4 pertussis toxins or cholera toxin H snbunit, However, one difficulty with the production of live attenuated vaccines is that during bulk culture the organism does not always express some proteins which a!-e i:npozrtant for host protection. In addition, once such vaccines have been administered to S the host, the vaccine strain does not have the optimum time cr metabolic rescu,~c.es during its limited colonisation to express These protein in vivo to a sufficient level tc roofer protection.
Summary of the Invention.
J. ~ The present invention is based on the finding that altering the regul.ition oFthe ferric uptake regLlotion i;,rur) gene in l'~r meningitides, such that its o~:pression is independe~,t of the iron concon~ation in the environment of the bacterium.
enhances the expression of important protecti;re antigens when the bact-.rium is c own in cultu-e.
This has important implications for the manufacture of live vaccines since the increased 1 ~ e::pression cf these protective antigens during the manufacture process will incraase the efficacy of the live vaccine when administered to an anzmaE or human st:bject.
Thus in a first aspect the invention provides an attenuated bacterium in which the native.~.cr gene, or homologue thereof.; is modified such that the e~-pression ~:,f the fz~r gene product, or horr~ologue Hereof, is reguiatcd independently of the i:on concer_wation %t~ :n the environment of the bacterium. The attenuated bacterium is preferabl;~ a. C s,m-negative bacterium, for example selected from the generaNeisseria, .Heh:rb~~cN~r, ,Salna.onella, Esrhericlzia, Yibrio, Shigella, I~Taernoprlilur, Bord~teih~, Bseudcn~nas, .Iersinia and Bruceila. More preferably the bacu:riu~-n is sel:cted from the C
oup consisting of ~J ~r~eningi~idts, u: gonorrhoeae, Helicobacter~vlori, Sainzonella slip.
~5 (including S. tvplZi aid S. typhi~azurium); enteropathoger,.ic E. coli (>r'°EC), w;.eroinvasive .~. coli (EIIIC), enterotoxigenic .E. coli (h:TEC) enterohaemerrhagic ~'. oily (hHBC), >>erctoxigenic E. coli (V'fBC); Yibrio choleric, Sh:gella spp., Haerf~onhilus influer~,ae, Bordetalla pertussis and Pseudomonas aeruginosa.
Especia'ly preferred are N, meningitidis and Ir' gonorrhoeae, most pzeferably ~~'.
meringi~~dis.
30 Preferably, the bacterium has been attenuated by mutation of a gene essential for the production of a metabolite or catabolite not pz-oduced by a human or animal. 'fh~
mutated gene is most desirably an aro gene such as an aroA, aroB, aroC, aroD
or aroL
gene or a gene of the pun or pyr pathways such as pur.~4, purB, p~L, pyTA, pyrB er pyr~E.
'' The aroB or aroL gene is preferred, in particluar for lJ. meningitidis.
When the 35 bacterium is N. meningitidis or 11~.
CA 02292900 1999-12-03 AM~NOED ~HEEr
diphtheria toxin, ~~~,,;.,. .., w~, .b, EMGFG,~EPA-Munchen 05 ;11- 8-99 ; 18.58 ~ 0171 242 8°22-' ~~ 4 pertussis toxins or cholera toxin H snbunit, However, one difficulty with the production of live attenuated vaccines is that during bulk culture the organism does not always express some proteins which a!-e i:npozrtant for host protection. In addition, once such vaccines have been administered to S the host, the vaccine strain does not have the optimum time cr metabolic rescu,~c.es during its limited colonisation to express These protein in vivo to a sufficient level tc roofer protection.
Summary of the Invention.
J. ~ The present invention is based on the finding that altering the regul.ition oFthe ferric uptake regLlotion i;,rur) gene in l'~r meningitides, such that its o~:pression is independe~,t of the iron concon~ation in the environment of the bacterium.
enhances the expression of important protecti;re antigens when the bact-.rium is c own in cultu-e.
This has important implications for the manufacture of live vaccines since the increased 1 ~ e::pression cf these protective antigens during the manufacture process will incraase the efficacy of the live vaccine when administered to an anzmaE or human st:bject.
Thus in a first aspect the invention provides an attenuated bacterium in which the native.~.cr gene, or homologue thereof.; is modified such that the e~-pression ~:,f the fz~r gene product, or horr~ologue Hereof, is reguiatcd independently of the i:on concer_wation %t~ :n the environment of the bacterium. The attenuated bacterium is preferabl;~ a. C s,m-negative bacterium, for example selected from the generaNeisseria, .Heh:rb~~cN~r, ,Salna.onella, Esrhericlzia, Yibrio, Shigella, I~Taernoprlilur, Bord~teih~, Bseudcn~nas, .Iersinia and Bruceila. More preferably the bacu:riu~-n is sel:cted from the C
oup consisting of ~J ~r~eningi~idts, u: gonorrhoeae, Helicobacter~vlori, Sainzonella slip.
~5 (including S. tvplZi aid S. typhi~azurium); enteropathoger,.ic E. coli (>r'°EC), w;.eroinvasive .~. coli (EIIIC), enterotoxigenic .E. coli (h:TEC) enterohaemerrhagic ~'. oily (hHBC), >>erctoxigenic E. coli (V'fBC); Yibrio choleric, Sh:gella spp., Haerf~onhilus influer~,ae, Bordetalla pertussis and Pseudomonas aeruginosa.
Especia'ly preferred are N, meningitidis and Ir' gonorrhoeae, most pzeferably ~~'.
meringi~~dis.
30 Preferably, the bacterium has been attenuated by mutation of a gene essential for the production of a metabolite or catabolite not pz-oduced by a human or animal. 'fh~
mutated gene is most desirably an aro gene such as an aroA, aroB, aroC, aroD
or aroL
gene or a gene of the pun or pyr pathways such as pur.~4, purB, p~L, pyTA, pyrB er pyr~E.
'' The aroB or aroL gene is preferred, in particluar for lJ. meningitidis.
When the 35 bacterium is N. meningitidis or 11~.
CA 02292900 1999-12-03 AM~NOED ~HEEr
-5-gonorrhoeae, it may also carry a galE mutation. Optionally the galE mutation is accompanied by modification or elimination of expression from the opc gene. Attenuation mutations may be provided in one or more, for example two or three, genes.
In yet another preferred aspect, the bacterium further comprises a recA
mutation.
Optionally, in addition to or instead of the recA mutation, the bacterium also comprises a mutation in a gene responsible for the uptake of DNA. These gene mutations will provide attenuated strains in which the possibility of homologous recombination with DNA from wild-type strains has been minimised. Such a gene may include the comA pilin gene of N. gonorrhoeae (Molecular Microbiology (1993) 10: 699-712) or its homologues in other species - particularly N. meningitides - which may be obtained by methods analogous to those described herein for other genes.
Further modifications may be made for additional safety. For example the bacterium may additionally comprise a mutation in which expression of toxin genes has been modified or eliminated. In particular, for Neisseria species, the RTX (repeats-in-toxin) toxin gene may be modified or eliminated. This is accomplished by deleting the frpA gene in the frp polycistronic locus, while maintaining the correct reading frame for the polycistron to retain expression of outer membrane proteins which may be important for the efficacy of the vaccine.
Certain bacteria such as N. meningitides and others mentioned above are known to produce membrane vesicles. This is caused by aberrant cell division resulting in DNA-less cells (or mini-cells) which bud from the dividing bacteria. Such membrane vesicles, particularly of N. meningitides, form a further aspect of the invention. Production of such vesicles is enhanced by mutation in the locus homologous to the E coli mina locus and thus in a fiu~ther aspect of the invention mutations in these genes may be made.
Particularly preferred strains of N. meningitides have the genotypes: DaroB, lac:fur fusion; aroB, lac:fur fusion, recA; aroB, galE, lac fur fusion, recA; aroL, lac:fur fusion, recA; aroL, galE, lac:fur fusion, recA. The strains may further comprise at least one of a mina mutation, an RTX negative phenotype, modified expression of the opc gene and/or an additional attenuation mutation in a second aro gene, purB, purE, pyrA or pyrB.
The invention further provides a vaccine preparation which comprises a bacterium or a vesicle preparation of the invention together with a pharmaceutically acceptable diluent or carrier. Such vaccines may be used in a method of treatment of the human or animal body.
Such a method may comprise protecting an individual against a bacterial infection by
In yet another preferred aspect, the bacterium further comprises a recA
mutation.
Optionally, in addition to or instead of the recA mutation, the bacterium also comprises a mutation in a gene responsible for the uptake of DNA. These gene mutations will provide attenuated strains in which the possibility of homologous recombination with DNA from wild-type strains has been minimised. Such a gene may include the comA pilin gene of N. gonorrhoeae (Molecular Microbiology (1993) 10: 699-712) or its homologues in other species - particularly N. meningitides - which may be obtained by methods analogous to those described herein for other genes.
Further modifications may be made for additional safety. For example the bacterium may additionally comprise a mutation in which expression of toxin genes has been modified or eliminated. In particular, for Neisseria species, the RTX (repeats-in-toxin) toxin gene may be modified or eliminated. This is accomplished by deleting the frpA gene in the frp polycistronic locus, while maintaining the correct reading frame for the polycistron to retain expression of outer membrane proteins which may be important for the efficacy of the vaccine.
Certain bacteria such as N. meningitides and others mentioned above are known to produce membrane vesicles. This is caused by aberrant cell division resulting in DNA-less cells (or mini-cells) which bud from the dividing bacteria. Such membrane vesicles, particularly of N. meningitides, form a further aspect of the invention. Production of such vesicles is enhanced by mutation in the locus homologous to the E coli mina locus and thus in a fiu~ther aspect of the invention mutations in these genes may be made.
Particularly preferred strains of N. meningitides have the genotypes: DaroB, lac:fur fusion; aroB, lac:fur fusion, recA; aroB, galE, lac fur fusion, recA; aroL, lac:fur fusion, recA; aroL, galE, lac:fur fusion, recA. The strains may further comprise at least one of a mina mutation, an RTX negative phenotype, modified expression of the opc gene and/or an additional attenuation mutation in a second aro gene, purB, purE, pyrA or pyrB.
The invention further provides a vaccine preparation which comprises a bacterium or a vesicle preparation of the invention together with a pharmaceutically acceptable diluent or carrier. Such vaccines may be used in a method of treatment of the human or animal body.
Such a method may comprise protecting an individual against a bacterial infection by
-6-administering to an individual an effective amount of a vaccine composition comprising an attenuated bacterium, according to the present invention, normally associated with said infection.
The invention further provides a process for preparing a vaccine composition comprising an attenuated bacterium according to the invention which process comprises (a) inoculating a culture vessel containing a nutrient medium suitable for growth of said bacterium;
(b) culturing said bacterium; (c) recovering bacteria from the culture and (d) mixing said bacteria with a pharmaceutically acceptable diluent or carrier.
The present invention also provides a method for producing a bacterium according to the invention which method comprises modifying the native fur gene, or homologue thereof, of an attenuated bacterium such that expression of said fur gene or homologue is regulated independently of the iron concentration in the environment of the bacterium.
Preferably, said bacterium has been attenuated by mutation of at least one gene essential for the production of a metabolite or catabolite not produced by a human or animal, more preferably by a mutation of an aro gene such as an aroB gene and/or aroL gene and/or a gene of the pur or pyr pathways, in particular a purE, purB, pyrA and/or pyrB gene.
Brief Description of the Drawings.
Figure 1 illustrates the construction of the suicide/transformation vector pGITS.
Figure 2 shows the primers used for the amplification of the aroB gene from Neisseria meningitides and construction of an aroB deletion mutant.
Figure 3 illustrates the construction of an aroB deletion mutant Figure 4 illustrates the construction of an asd mutant Figure 5 illustrates the production of a furllac fusion strain.
Detailed Description of the Invention.
The term "vaccine" as used herein means an agent used to stimulate the immune system of a vertebrate, particularly a warm-blooded vertebrate including humans, so as to provide protection against future harm by an organism against which the vaccine is directed. The immune system can provide two types of responses to foreign organisms - cell-mediated (T cell) and humoral (B cell/antibody) responses. Both types of responses can be stimulated by a _7_ suitable vaccine to produce a primary immune response which leads to the development of immunological memory, providing protection against a subsequent infection by a pathogen.
Stimulation of the cell-mediated immune system results in the development of naive T cells into effector T cells which are able to react much more quickly to future challenges. Stimulation of B cells of the humoral immune system leads to the production of antibodies, desirably neutralising antibodies/ bacteriocidal antibodies, directed to epitopes found on or in the attenuated bacterial strain. The antibody so produced may be any of the immunological classes, such as the immunoglobulins A, D, E, G or M. Vaccines which stimulate the production of IgA
are of particular interest since this is the principle immunoglobulin produced by the secretory system of warm-blooded animals, and the production of mucosal antibodies will help prevent infection or colonisation of the nasopharynx, which is one natural route of infection of bacteria including N. meningitides. However, this and other organisms may also be infectious via the bloodstream and thus an IgM and IgG response will also be desirable.
The bacterium of the invention may be in isolated form. This is usually desirable when the bacterium is to be used for the purposes of vaccination. The term "isolated" means that the bacterium is in a form in which it can be cultured, processed or otherwise used in a form in which it can be readily identified and in which it is substantially uncontaminated by other bacterial strains, for example non-attenuated parent strains or unrelated bacterial strains. The term "isolated bacterium" thus encompasses cultures of a bacterial mutant of the invention, for example in the form of colonies on a solid medium or in the form of a liquid culture, as well as frozen or dried preparations of the strains.
The term "mutation" and the like refers to a genetic lesion in a gene which alters the levels of expression of the gene or the activity of the gene product. Such a mutation may exert its effect on the levels of expression of a gene product at any stage from the level of transcription to the level of translation and protein stability.
Alternatively, a mutation may cause in a change in the coding sequence such that the resulting gene product has altered activity, generally reduced activity. For example, an "inactivating mutation"
would render the gene non-functional. The term "inactivating mutation" thus envisages deletion of the entire gene or substantial portions thereof, and also point mutations in the coding sequence which result in truncated gene products unable to carry out the normal function of the gene. Where deletion of a portion of a gene is carried out, it may be desirable to introduce frame shift mutations downstream of the deleted region to remove the possibility of small sections of the _g_ gene being expressed.
A mutation introduced into a bacterium of the invention will generally be a non-reverting attenuating mutation. Non-reverting means that for practical purposes the probability of the mutated gene being restored to its normal function is small, for example less than 1 in 106 such as less than 1 in 109 or even less than 1 in 10'Z. However despite this, it may be considered desirable that a bacterium for use as a live attenuated vaccine should carry at least two attenuating mutations. Usually these mutations will be in separate genes.
An "attenuating mutation" is a mutation in a gene which is required for the growth of a bacterium. Such a gene is thus usually a metabolic, for example a catabolic or biosynthetic, 1 o gene. Preferred attenuating mutations are made in genes which are required for the production of an essential nutrient or intermediate which is not available in the tissues of the human or animal host in which the bacterium is normally pathogenic. Thus the attenuated bacterium will not be able to simply obtain the essential nutrient or intermediate from the infected host.
A bacterium of the invention will be an attenuated form of a pathogenic bacterium. The term "pathogenic" means that the bacterium is capable of causing disease in a human or animal (especially avian or mammalian, including human) host, although in some cases the bacterium may be carried asymptomatically by healthy individuals. Examples of the latter type include N. meningitides and S. aureus.
Production of Bacteria The survival of any bacterium in a given environment depends on its ability to obtain all its growth requirements in competition with other resident organisms. It must express those proteins which are essential for growth and replication if it is to be competitive and survive.
Strains which carry a particular mutation or combination of mutations may be made from a species of bacteria in accordance with the present invention. These strains will carry particular genetic lesions or mutations which render the organism auxotrophic for an essential nutritional requirement. If the organism is unable to acquire this nutrient from its environment it will not proliferate and will die once endogenous levels are exhausted. If such mutations are incorporated into normally pathogenic bacteria and the essential nutrient or its intermediates are absent from the tissues of the host then that mutant organism will be attenuated and unable to establish a normal infection, if colonisation is a component of the infection process.
Bacterial strains according to the invention may be constructed using recombinant DNA
WO 98!56901 PCT/GB98/01683 _g_ methodology which is known per se. In general, bacterial genes may be mutated by a process of targeted homologous recombination in which a DNA construct containing a mutated form of the gene is introduced into a host bacterium which it is desired to attenuate.
The construct will recombine with the wild-type gene carried by the host and thus the mutated gene may be incorporated into the host genome to provide a bacterium of the present invention which may then be isolated.
Various assays are available to detect successful recombination. In the case of attenuations which mutate a target gene necessary for the production of an essential metabolite or catabolite compound, selection may be carried out by (i) screening for bacteria unable to grow in the absence of such a compound; (ii) genetic methods to determine the deletion of the gene and/or (iii) showing that a genetically determined mutant can not grow in human fluids, for example blood or cerebrospinal fluid.
The mutated gene may be obtained by cloning the wild-type gene from the bacteria which is to be attenuated, or from a closely related species, and manipulating it by standard recombinant DNA techniques. These include introducing deletions into the gene, e.g. by digesting with a restriction enzyme which cuts the coding sequence twice to excise a portion of the gene and then religating under conditions in which the excised portion is not reintroduced into the cut gene. Alternatively frame shift mutations, which alter the reading frame of the DNA sequence, may be introduced by cutting with a restriction enzyme which leaves overhanging 5' and 3' termini, filling in and/or trimming back the overhangs, and religating.
Similar mutations may be made by site directed mutagenesis. These are only examples of the types of techniques which will readily be at the disposal of those of skill in the art. Another example is PCR of flanking regions adjacent to the target gene followed by ligation to form a deletion mutation construct.
The cloning of the wild-type gene may be undertaken using PCR cloning methods which are also known per se in the art. Such methods require knowledge of at least part of the sequence of the gene which is to be mutated. The sequence may be obtained by reference to databases such as Genbank. Where a gene sequence is not known for a particular organism, consensus sequences may be determined by aligning sequences of corresponding genes of other, related, organisms and determining regions which are most conserved. For example, the aro, pur and pyr genes of N.meningitidis can be isolated by screening the N.gonorrhoea raw database for sequences that have similarity to E.coli proteins. The appropriate gene sequences can be identified and primers designed for amplification of the corresponding genes of N.meningitidis. In general, many genes, especially those of metabolic and catabolic pathways are well conserved between gram-negative bacteria and appropriate PCR primers can be determined without difficulty.
The above techniques are exemplified further in the Examples below and can be readily adapted to provide other embodiments of the invention. Reference may also be made to, for example, Sambrook et al., "Molecular Cloning - A Laboratory Manual" (Cold Spring Harbor, 1989) or "Short Protocols in Molecular Biology - A Compendium of Methods from Currrent Protocols in Molecular Biology" eds. Ausubel et al. (John Wiley & Sons, 1992).
Attenuating Mutations.
An attenuating mutation can, for example, be made in a gene encoding a component of a metabolic pathway so that the growth of the attenuated bacterium is inhibited due to a lack of an essential metabolic intermediate of a particular metabolic pathway. Growth of such attenuated bacteria can then be achieved in culture by supplying the essential metabolic intermediate in the culture medium. However, when such attenuated bacteria are administered to a human or animal host for vaccination purposes, it is clearly desirable that the host itself is not able to supply the essential metabolic intermediate required by the attenuated bacterium for optimum growth. Consequently, attenuating mutations are preferably made in genes essential for the production of a metabolite, for example an anabolite or catabolite, not available in the human or animal host which is to be vaccinated.
Particular examples of pathways whose genetic components may be inactivated by mutation include 1. aromatic amino acid biosynthetic pathways, 2. purine biosynthetic pathways and 3. pyrimidine biosynthetic pathways.
1. Aromatic ring~biosynthetic pathways - The shikimic acid pathway This pathway is involved in the biosynthesis of virtually all aromatic compounds but is not present in mammals. It is therefore particularly preferred that mutations are made in genes encoding components of this pathway. The enzymes catalysing the various reactions of the shikimic acid pathway (and their corresponding genes) include 3-dehydroquinate synthase (aroB), 3-dehydroquinate dehydratase (aroD), shikimate dehydrogenase (aroE), shikimic acid kinase I (aroK), shikimic acid kinase II (aroL), 5-enoylpyruvyl shikimic acid 3-phosphate (aroA) and chorismate synthase (aroC).
A lesion in any of the genes of the shikimic acid pathway would render the bacterium auxotrophic for the essential nutrient chorismate. If the lesion occurs in a gene of the pathway prior to shikimic acid kinase I (aroK) but not in any of the downstream genes the bacterium will also be auxotrophic for the essential nutrient shikimate. Since these compounds are essential for aromatic amino acid biosynthesis in gram-negative and some gram-positive organisms and are absent from mammalian or other vertebrate tissues, mutants would undergo lysis after about three rounds of division in such tissues. Such a mutation will limit the proliferation of the bacteria in host tissues but will not affect their growth during vaccine production since the essential nutrients or aromatic amino acids can be provided exogenously during bulk culture of the vaccine strain.
The invention provides, in a particularly preferred embodiment, a live attenuated vaccine which is effectively attenuated by construction of specific deletion and frame-shift mutations initially in the aroB gene. The Neisseria gonorrhoeae aroB gene has been cloned and its nucleotide sequence deposited in Genbank as Accession No. AJ002783.
It is also particularly preferred that an attenuated bacterium of the invention has an inactivating mutation in the aroL gene, in addition to or instead of an inactivating mutation in the aroB gene. The E. coli aroL gene is described in Biochem J. (1986) 237(2):
{Genbank Accession No. X04064).
Functional inactivation of the aroA gene is preferably a secondary mutation once a primary mutation in one of the other aro genes (or one of the other genes described below) has been carried out. The E. coli aroA gene is described in FEBS Lett. (1984) 170:
59-63 (Genbank Accession No. X00557).
Mutations in aroC and aroD have been described in EP-A-322 237. The E.coli aroC
gene is described in Biochem J. (1988) 251(2): 313-322 (Genbank Accession No.
Y00720).
The Neisseria gonorrhoeae aroD gene is described in Mol. Gen. Genet. ( 1997) 254(5): 479-485 (Genbank Accession No. U39803). The Neisseria meningitides aroE gene is described in Mol.
Microbiol. 23(4): 799-812 (1997) (Genbank Accession No. U82841).
2. Purine biosynthetic~athways Mutations in any of the genes in the pur pathway (e.g. purB (encoding adenylosuccinate lyase) or purE (encoding 5'-phosphoribosyl-5-amino-4-imidazole carboxylase)) will render the organism auxotrophic for purines, essential constituents of nucleic acids.
Many of the intermediates of the pathway are unavailable in mammalian or other vertebrate tissues.
3. Pyrimidine biosynthetic pathways Mutations in any of the genes in the pyr pathway (e.g. pyrA (encoding carbamyl phosphate synthetase) or pyrB (encoding aspartate transcarbamylase)) will render the organism auxotrophic for pyrimidines, essential constituents of nucleic acids. Many of the intermediates of the pathway are unavailable in mammalian or other vertebrate tissues.
Other genes which may be mutated include the asd gene which encodes aspartate-semilaldehyde dehydrogenase. Mutations in asd would not be made as a primary mutation and would instead be made subsequent to a primary mutation in one of the other genes described above. The N. rneninigitidis asd gene is described in Gene (1993) 129(1): 123-128 (Genbank Accession No. Z14063).
Inactivating mutations may be made in only one of the genes described above (or another suitable gene) or alternatively, mutations in multiple genes may be employed, for example with mutations in the aroB gene as the primary mutation followed by mutations in at least one of the other genes. A double or triple mutant may be useful from the safety point of view since it will be more attenuated, but such a double mutant may also be less efficient as a vaccine. Strains with different levels of attenuation may be assessed during trials for their degree of efficacy and any side effects. Mutations of any of these genes may be accomplished, for example, in a similar way to that described for aroB in the Examples.
Mutation to maximise exposure of important epitopes The galE gene codes for UDP-galactose-4-epimerase. In Neisseria this enzyme does not appear to have a role as part of the galactose biosynthesis pathway, but it is involved in the incorporation of galactose into the phase-variable oligosaccharide side chains of LPS/LOS. N.
meningitidis contains two chromosomal galE sequences, galEl and galE2 at separate loci.
GalEl is complete, expressing a functional gene product, while galE2 is truncated, and lacks homology over the first third of the protein. The galE gene and its role in biosynthesis of LOS/LPS is described in Molecular Microbiology (1993) 10: 361:369.
A mutation in the galE gene denudes and shortens the LPS of galactose residues. Thus, a galE deletion exposes the constant region of the LPS to the immune system.
which leads to the generation of a cross-protective response. The reduction in the length of LPS may reduce the capsule on the surface of the organism. A further effect of a galE
mutation and the resulting short LPS is that outer membrane proteins exposed on the cell surface will become more accessible to the hosts immune system potentially leading to an improved immune response to the vaccine strain. Thus incorporation of a galE mutation, rendering the gene non-functional, into a Neisseria strain of the invention is preferred.
In addition, without the incorporation of galactose into the LPS the potential autoantibody-producing epitopes of LPS will not be incorporated. These epitopes are normally found on host epithelial cells and in many host secretions. Thus their removal from vaccine strains will greatly reduce the danger of immunopathological effects of the vaccine.
It has also been shown in bacteria, particularly N. meningitides, that the galE mutation results in an increase in opc-mediated invasion. For a vaccine intended for nasal delivery, this may be advantageous in stimulating the initial host tissue response and subsequent mucosal immunity, while other mutations (such as in the aroB gene) V~rould limit the proliferation of invading bacteria to approximately three rounds of division, precluding the possibility of a systemic infection. Aiso there is some evidence that galE mutants are serum sensitive and therefore would be rapidly killed if they entered the hosts circulatory system.
A mutation in a capsule gene, cap, may also result in increased exposure of epitopes.
That may in turn result in an increased immune response to the attenuated baterium.
Invasion/adhesion.
A galE mutation will expose the Opc protein thus making the vaccine strain able to colonise and invade into the blood stream more efficiently. This would be important to get a good mucosal and serum immune response in the limited time that the strains survive in the human body. There are two possible modifications to opc that may be made in accordance with one embodiment of the invention.
If there is excessive adhesion or invasion with the vaccine strain, then opc expression may be modified or even eliminated entirely. Where opc expression is found to be important for vaccine efficacy but is variable in expression, then opc may be placed under the control of another promoter e.g. cat, which can be more readily controlled. The opc opacity protein may be found by reference to the EMBL/GenBank/DDBJ databases. 1993. Accession number Z 14063 (Microb. Pathog ( 1991 ) 11:249-257).
Mimicking in vivo expression of iron re;,ulated proteins One failing of live attenuated vaccines in the past has been that during bulk culture the organism has not expressed some proteins which are important for host protection. Such proteins include iron regulated proteins, the production of which is regulated by the fur (ferric uptake regulation) gene. In addition, once such vaccines have been administered to the host, the vaccine strain has not had time or metabolic resources during its limited colonisation to express these proteins in vivo.
To overcome these problems, the present invention provides vaccine strains which have been modified such that many of the proteins which are likely to be important immunogens, e.g.
the iron regulated proteins, are already expressed on the cell surface during bulk culture. This is achieved by altering the regulation of the ferric uptake regulation (fur) gene (EMBL/GenBank/DDBJ databases. 1993. Accession number L19777, Mol. Microbiol (1994) 11(4): 725-737 (Neisseria); Mol. Gen. Genetics (1985) 200: 110-113 (E coli)).
The fur gene may be modified to produce its gene product independently of the iron concentration in the environment of the bacteria by any suitable means. In this context, the term "gene" is intended to encompass both the coding sequence of the fur protein together with any transcriptional/translation control sequences present, including promoters, transcriptional stop sequences, ribosome binding regions and other translation regulation elements.
Thus, modifications may be made to the coding sequence and/or the transcriptional/translation control sequences. For example, the promoter sequences of the gene may be determined (e.g. by reference to the database sequence and/or sequencing this region using PCR
primers directed upstream from the coding region) and the promoter regions responsible for iron concentration-dependent regulation may be modified by mutation, including deletion, insertion and/or substitution. One such identified promoter region is the fur box. Since fur expression may be required for positive regulation of some essential genes in Neisseriacae and complete inactivation of the fur gene is often lethal to the bacterium, the minimum levels of expression from the modified fur gene will preferably be sufficient to allow viable growth of the bacterium.
In particular, levels of expression from the modified fur gene are preferably at least equal to those obtained using the native fur gene in the presence of low levels of ferric ions, i.e. the maximal repressed state.
Alternatively the endogenous fur gene may be placed under the control of another promoter entirely. Such a heterologous promoter may be any promoter which is regulated independently of iron concentration and which functions in the host bacterium.
Preferably said promoter comprises a bacterial promoter such as a promoter derived from that bacterium or a member of the same family, or from a bacteriophage. Suitable promoters include both constitutive promoters such as that of the chloramphenicol resistance gene and regulatable promoters such as the promoters of catabolic, metabolic and biosynthetic genes, including those involved in the regulation of amino acid biosynthesis (which are induced when a required amino acid is absent or at a low concentration) or those involved in the metabolism of sugars (which are induced by the presence of the appropriate sugar). The trp promoter and the IacZ promoter are particular examples of the above, and the latter is especially preferred.
The promoter region of the endogenous fur gene is conveniently modified by homologous recombination with a suitable construct. The construct may comprise all or part of the fur gene together with the desired replacement promoter sequences provided that recombination results in modification of the endogenous fur gene.
Alternatively, the endogenous fur gene may be inactivated, and a complete fur gene together with the desired replacement promoter sequences introduced into the bacterial genome or maintained as an extrachromosomal plasmid. This will ensure that even in the presence of iron tittle fur gene expression occurs, although the heterologous promoter wilt allow sufficient expression of any essential genes positively regulated by fur.
In a particularly preferred embodiment of the invention, to overcome the problems of regulating fur and also to mimic in vivo levels of expression of iron regulated genes, fur gene expression is placed under the control of the IacZ promoter/lacl repressor which confers positive regulation of -galactosidase in the presence of lactose. Preferably, the 19 mutation in lacl is included which increases the basal level of expression ten-fold. This provides for sufficient production of fur to allow expression of essential genes and also allows the control of fur expression to be regulated in response to intracellular lactose concentrations.
Mutations may also be made in the coding sequence of the fur gene, which encodes the fur protein. By way of example, a mutation can be made which modulates the affinity of the fur protein for ferric ions. Preferably, such a mutation would abolish or substantially reduce the affinity of the fur protein for ferric ions. In this way, the fur proteins transcriptional regulatory functions would be independent of the iron concentration in the environment of the bacterium.
WO 98!56901 PCT/GB98/01683 Preferably, an attenuated asd mutant is used and its fur gene replaced with a fur gene under the control of the lacZ promoter/lacl repressor. The resulting low levels of the fur protein would enable the negatively regulated fur-controlled genes to be switched on, mimicking iron restricted conditions. The strain would therefore be fully attenuated but would fully express all iron-regulated proteins before being administered to the recipient without the need for iron-restricted growth conditions. The host would then be able to mount an immune response that would mimic that in response to the wild-type pathogen.
Thus placing fur under the regulation of the lacZ promoter is preferred. This allows its expression only in the presence of lactose or one of the non-metabolisable lactose analogues such as IPTG. Since the lac inducer dissociates from the lac operator in the presence of lactose, fur expression can be reduced down to basal levels by growing the strain in the absence of lactose. This effectively up-regulates all fur regulated genes mimicking growth in low iron, in vivo conditions. The result will be that in the absence of lactose, the bacteria will respond as if they are experiencing iron restricted conditions, producing the iron regulated proteins normally expressed in vivo, without the use of large quantities of iron chelators. It is thus possible to control fur expression independent of the iron concentration in the medium.
Fur expression will only be at "trickle through" basal levels in the absence of lactose. The maintenance of this basal level of expression is thought to be important for cell viability.
Therefore, in this embodiment of the invention, when the vaccine is administered to the host, many of the important proteins will already be present on the bacterial surface. This will relieve the metabolic burden that the bacterium will experience in vivo, freeing the resources of the bacterium to express other in vivo regulated proteins which are not iron regulated but are important for host protection.
The production of attenuated strains of bacteria in which the expression of fur has been modified as described above is a generally applicable technique. Thus any normally pathogenic bacterium which has a genome comprising a fur gene or homologue thereof, which bacteria is attenuated by deletion or modification of a gene essential for growth in a host in which the bacteria is pathogenic, may be modified as described above so that it produces the fur gene product, or homologue thereof, independently of the iron concentration in the environment of the bacteria. Fur homologues can be identified by sequence comparison with other known fur gene sequences from, for example E. coli and N. meningitides. Preferably, such homologues are substantially homologous to another known fur gene. In particular it is preferred that homologues have sequence identity of at least 60% at the amino acid level, more preferably 70%, over a stretch of at least 100 amino acids. Fur homologues can also be identified on the basis of function. The product of the fur gene in Neisseria controls the expression of numerous genes including those encoding toxins and iron uptake components, and is responsive to ferric ion concentrations. Thus genes identified in other bacteria which encode transcription factors which also have these ferric iron-responsive properties may be used.
Mutations to achieve genetic isolation and stability.
Another consideration of live attenuated vaccines which has to be addressed is the genetic stability of the strain. The strain must not be able to revert to a wild-type phenotype, nor must it lose the ability to express genes important for host protection.
Genetic stability can be increased by introducing a deletion in the recA gene. This gene enables the organism to repair its DNA by homologous recombination. The recA mutation knocks out homologous recombination - the process which is exploited for the construction of the mutations. Once the recA mutation has been incorporated the strain will be unable to repair the constructed deletion mutations. A mutation in recA will also make the strain sensitive to ultra-violet light and will be an important containment factor.
In addition, it would prevent the strain from repairing the genetic lesions by homologous recombination using wild-type DNA found in the environment or the tissues of the host (commensal Neisseria for example). A recA mutation also increases the general stability of the strain by reducing the loss of phenotypic characteristics by deletions and inversions which are mediated at least in part by such recombination pathways. RecA genes have been widely studied in the art and their sequences are available. Reference may be made to EMBL/GenBanklDDBJ databases. 1992. ID code NM446REC (or Molecular Microbiology ( 1992) 6:213 S-2146).
In many cloning procedures, selectable markers are used to select desired mutants.
However, it may be preferred to remove subsequently the selectable marker.
Since introducing a recA mutation will disable the recombination apparatus of the bacterium it will not be possible to use a subsequent recA-dependent recombination event to remove the selectable marker. Thus a particularly preferred method for introducing a recA mutation which allows subsequent removal of a selectable marker is to flank the selectable marker sequences with sequences which are recognised by a recombinase/resolve-type enzyme. For example, the product of the parA
gene is a resolvase that specifically excises regions of chromosomal DNA
flanked by 140 by res sites (J. Bact. (1995) 177:52-58). Therefore the recA mutation cassette may comprise a selectable marker gene flanked by res sites. Once mutant bacteria with the desired recA
mutation have been selected, introduction of a plasmid encoding the parA
resolvase will result in excision of the selectable marker gene. Plasmid RP4 (J. Bact. (1995) 177:52-58) is an example of such a plasmid. Expression of the resolvase protein even at low efficiency will be sufficient to result in the excision of the selectable marker gene flanked by the res sites. The plasmid bearing the parA gene lacks a Neisserial origin of replication and would be lost naturally from Neisseria sp.
Additional genetic stability.
Once the recA activity has been abolished, the bacterial strain may still have some residual ability to take up exogenous DNA. This may vary from strain to strain. If the frequency of such events is considered too high (e.g. by regulatory authorities) a further mutation may be introduced to reduce DNA uptake. Such a mutation may be made in any gene involved in DNA uptake and would be made in a particular strain prior to the mutation of recA
if it is found that the recA mutation alone is not sufficient.
The comA gene of N. gonorrhoeae is involved in competence. A mutation in the comA
locus would render this organism unable to take up exogenously added DNA, making the strain genetically isolated, biosafe and more stable. Corresponding mutations at homologous loci may be made in N meningitides and other organisms. Those of skill in the art will appreciate that it will be necessary to recombine the recA and comA (or other gene involved in DNA uptake) constructs simultaneously, since both recombination and competence functions to introduce these lesions. Thus where a recA and/or comA lesion is required in a strain, this/these will be introduced as the final genetic modification, following the other modifications described herein.
RTX toxin.
The N. meningitides vaccine strains produced in accordance with the embodiments of the invention described above will still express the genes for the RTX toxin and its secretion machinery (encoded by frp locus). The outer membrane proteins for toxin secretion may be important protective antigens. However, the toxin itself, which is iron regulated, may cause some adverse reactions, for example in some subgroups of patients or with some attenuated strains. If the production of the RTX toxin causes problems during the limited colonisation of the vaccine strain, then the toxin gene will be inactivated by defined deletion or other modification. This will leave the genes for the outer membrane transport proteins intact, since they may be important elements for the efficacy of the vaccine.
One option would be to inactivate the toxin structural gene (frpA) by the insertion of a SacRB cartridge from B. subtilis . This would result in a sucrose sensitive phenotype which would provide a molecular tag, allowing genetic stability to be monitored during manufacture.
The RTX toxin gene may be found by reference to Mol. Micro (1993) 9:85-96.
Although an RTX mutation is envisaged primarily with reference to N.
meningitides, many other bacteria have a similar RTX toxin and corresponding mutations may be made in these. In addition, other bacteria produce other types of toxin and it may be necessary to introduce mutations into the genes encoding these toxins, using standard techniques.
Membrane Vesicles.
In addition to the live attenuated vaccine, membrane vesicles derived from this N. meningitides or other vesicle-producing bacteria may be a better option for certain patients or patient groups. N. meningitides and other bacteria naturally produce membrane vesicles which may be isolated. These may be used directly to induce a strong immune response.
Mutations in the E. coli mina locus (see Eur. J. Biochem. (1981) 116:331-335) cause aberrant cell division and the production of mini DNA-less cells. Mutations in this locus and homologous loci in other bacteria will greatly increase the production of membrane vesicles or mini cells by these bacteria. Thus the present invention also provides a bacterium with additional mutations in loci homologous to the E. coli mina locus (described in Cell (1989) 56:
641-649 - Genbank Accession No. J03153).
Strains of N. meningitides.
To provide attenuated strains of N. meningitides any suitable starting strain may be used.
In general, clinical isolates are preferred since these represent strains which have been shown to cause disease in patients. Clinical isolates include KH 454 Serotype B 15 P
1.7 (J. Med.
Microbiol. (1995) 42:353-361), nm3474 Serotype B2B P1.10 {available from Nottingham Public Health Laboratory Service, Nottingham, UK) and strain B 16:B6 (Schryvers et al, Microb. Pathog. 24, 75-87, 1998). However these are only examples and many clinical isolates are available in medical microbiology laboratories throughout the world.
Whatever starting strain is used, preferred genotypes of attenuated strains in accordance with the invention include the following:
1. aroB, galE, lac:fur fusion, recA.
2. aroL, galE, lac. fur fusion, recA.
In either case one or more of the following characteristics are additionally preferred:
i) a mutation in a homologue of mina ii) an RTX negative phenotype; and iii) an opc gene, the expression of which has been modified or eliminated.
iv) a mutation in a capsule gene.
l~~ menin~itidis as a carrier for other antigens.
Attenuated strains of the invention will also be useful as a vehicle for the delivery of other antigens from other pathogens, including viral and bacterial pathogens.
This will be useful where protection against such other pathogens can be obtained by stimulation of the immune system by such an antigen. Examples of this include the hepatitis B
surface antigen, pertussis toxin, V. cholerae or ETEC B subunit toxin or diphtheria toxin.
In these cases a gene encoding the antigen will be operably linked to a promoter capable of functioning in the bacterium of the invention to provide an expression cassette or vector and such a cassette or vector will be introduced into the bacterium. The cassette or vector may also comprise genomic sequences from said bacterium to allow for homologous recombination of the cassette or vector into the genome of the cell. For example, the cassette or vector may be designed such that the antigen gene replaces one of the genes described above which is to be attenuated.
Growth of strains and production of vaccines.
Once bacteria have been engineered in accordance with the invention, they may be grown in culture and the culture recovered to provide bacteria for a vaccine composition.
Conditions for the growth of bacteria are well known in the art, and industrial processes for recovery of bacteria are also widely available.
Vaccine preparations.
The bacteria of the invention, or the membrane vesicles, may be formulated into vaccine preparations. Typically vaccines are prepared by mixing the bacteria with a pharmaceutically acceptable carrier or diluent. Such carriers or diluents include water, saline, dextrose, trehalose, glycerol, ethanol or the like, or mixtures thereof. The vaccines may comprise one bacterial strain or a mixture of strains (i.e. either a mixture of different types of the same species and/or different species).
The concentration of the attenuated strain in the vaccine will be formulated to allow convenient unit dosage forms to be prepared. Concentrations of from about 10° to 109 bacteria per ml will generally be suitable, e.g. from about 1 OS to 1 O$ such as about 1 O6 per ml. Where membrane vesicles are formulated, suitable concentrations will be in the range of from about I
to 100, e.g. 5 to 50 mg of protein per ml.
The vaccine composition may, for example, be formulated as an aerosol, particularly for N. meningitides, at concentrations the same as those described above and as a preparation for injection.
Administration of vaccines.
The vaccines of the invention may be administered to recipients in order to protect them against diseases caused by the corresponding wild type organism. Although human recipients are primarily envisaged - especially for N. meningitides which causes disease in humans vaccines of the invention will have veterinary uses, for example in vaccinating domestic pets such as cats and dogs, and in vaccinating livestock such as mammals including cattle, sheep and swine or other vertebrates such as poultry. These animals may be vaccinated in particular with attenuated enteric bacteria of the invention.
The vaccine may be administered by any suitable route. In general, subcutaneous or intramuscuiar injection is most convenient. This will lead predominately to a serum immune response which should prevent dissemination of the organism, throughout the body and the resulting septicaemia Because it is unknown whether this route of administration will provide any protection against colonisation of the nasopharynx and carriage, vaccinations against bacteria which also invade through this route may also be by use of an intranasal spray. This will lead to colonisation of the nasopharynx mimicking closely the natural route of infection and carriage.
The expected immune responses will be (a) mucosal - which would generate mucosal antibodies and should prevent colonisation by pathogenic bacteria and (b) serum - which should prevent dissemination of the bacteria throughout the body and the resulting septicaemia. This route of administration is particularly preferred for vaccination with attenuated strains of N. meningitides.
Indeed, for N. meningitides it is intended that this vaccine strain will primarily be delivered as a nasal aerosol, allowing the strain to colonise the nasopharynx (the initial site of colonisation for the wild-type organism). Due to the aro and the galE
mutations the strain will exhibit a limited invasion of the tissues and possibly entry into the blood stream before viability is lost through serum killing and autolysis. This will mimic closely the progression of the natural route of infection, producing mucosal and serum immunity. This may be boosted if desired by injection.
For infants where there may be some reluctance to vaccinate with a live attenuated vaccine, non-viable membrane vesicles may be used. As described above, such vesicles are naturally produced by lV. rneningitidis and can be harvested as a vaccine to be administered subcutaneously, intramuscularly or by nasal aerosol.
Doses of vaccine will ultimately be at the discretion of the physician, taking into consideration the status (e.g. age, weight, disease status) of the recipient and the nature of the vaccine strain used. However some general guidance may be found by reference to the published literature.
For example, intranasal doses of N. meningitides may be calculated by reference to animal models such as those disclosed in Microbial Pathogenesis (1992) 12:415-420 or Canadian Journal of Microbiology (1984) 30:1022-1029. Suitable intranasal doses are around 105 to 108, e.g. about 106 or 10' organisms in a single dose.
Live attenuated organisms may be administered subcutaneously or intramuscularly at up to 108 organisms in one or more doses, e.g. from around 105 to 108, e.g. about 106 or 10' organisms in a single dose.
Membrane vesicles may also be administered subcutaneously, intramuscularly or nasally in an amount of about 25-100 mg of protein (depending on LPS content of vesicles) in 2-3 doses. (See for example Infection and Immunity (1996) 64:2745-2751, Infection and Immunity (1995) 63:4642-4652 or Infection and Immunity (1995) 63:3531-3536).
The recipient may receive one or more doses, in the latter case the doses may be repeated at an interval of from one week to one or more months, e.g. 2, 3, 6, 12, 18 or 24 months.
The above doses are provided primarily with reference to adult humans. They may be scaled up or down in proportion to body weight for non-adults or for other species.
The invention will be described with reference to the following Examples, which are intended to be illustrative only and non-limiting.
EXAMPLES
Materials and Methods Gene construction The following PCR primers were synthesised for use in the genetic construction of vaccine strains. The primers were designed to contain a restriction site for ease of manipulation of the amplified products.
PRIMERS
Name - Gene - Sequence - Direction - Enzyme T G
aro 1 - aroA - GGAATTCGATTCCGATGATATCCGTCATATG - forward - EcoRl CAG C CG G C C
C
Aro2 - aroA - GGAATTCATCAGGAATATGATTCATATCCAT - reverse - EcoRl G G G G G G
AroB 1 - aroB - GCAGATGCCCGAAGCTTTTTATAGCGG
AroB2 - aroB - GAGCTCGGTACCGTGCAGCGTGTCCAGATCTGCAAG
AroB3 - aroB - CATAAAGGGATCCTGGTTCGCCAG
AroB4 - aroB - GGTACCGAGCTCCAAATGAAGGCAGATCTCGTCGCCC
AsdA - asd - ACAATGAAAGTAGAATTCGTCGGCTGG - forward - EcoRl C
AsdB - asd - GAATGCGGAGATGAATTCGCCGCCCAT - reverse - EcoRl G C T
FurD - fur - CCCTGCTCACGTCGACCAG - reverse - SaII
FurE - fur - ACGCGGTCGACGCTGCACG - forward - SaII
FurF fur -AATACGCAATTGGATCCTGCTTGC - reverse - BamHI
FurG - fur - GATATTGAATCATATGGAA.AAATTC - forward - NdeI
galEA - galEl - GTGATTTTGGATAAGCTTTGCAATTCC - forward - HindIII
galEB - galEl - CCAGCGCCATGAAGCTTCCATCAT - reverse - HindIII
lacl - lacl - GACAGGATCCAATGGTGCAAAACC - forward - BamHI
lac3 - lacZ - AATCATGGTCATATGTGTTTCCTG - reverse - NdeI
recAl - recA - CGGAATTCGGTCTGAAGCGGATG - forward - EcoRI
recA2 - recA - CGCAGCAGGAATTCCCGTTTATCG - reverse - EcoRI
These primers were used for amplifying target DNA to obtain copies of wild-type genes from target starting strains of bacteria. To obtain target DNA, 80 ml of overnight culture were grown in broth and harvested in 2 x 50 ml polypropylene tubes. The bacteria were recovered and DNA obtained using a standard phenol-chloroform extraction protocol.
Target genes were amplified by PCR under appropriate conditions carried out for 35 cycles, with the final cycle having an extension at 72°C for 9.9 minutes so that all extensions are completed. The purity, size and amount or PCR product obtained from any amplification is determined simply by agarose gel electrophoresis. 10 1 of the PCR reaction are analysed by agarose gel electrophoresis on a 1 % agarose gel and different size DNA
fragments separated and identified under UV light by staining with ethidium bromide. The size of the amplified DNA fragment was determined by comparison with known size markers. The amplified product was cloned into one of a range of vectors including pUC 19, pCRII, PCRscript and pSP72.
The above techniques may all be found in standard reference books such as Sambrook et al.., Cold Spring Harbor, 1989.
Mutants were constructed in vitro by identifying restriction enzyme sites from the information obtained by the sequencing of the cloned PCR product. Once restriction sites) in the desired areas) are identified, the cloned fragment is cut with the appropriate enzyme(s), removing a fragment from the centre of the cloned insert. 1'he plasmid is then re-legated and deletion derivatives identified by the reduction in size on agarose gels and by sequencing. This procedure is used to develop defined mutations in the genes aroA, galE, asd and recA.
Vectors Vectors used for transformation of N. meningitides include uptake sequences to assist with uptake of the vector by the bacterium. These sequences comprise a 10-mer inverted repeat (Goodman and Socca, Proc. Natl. Acad. Sci. (1988) 85:6982-6986). The nucleotide sequence of the uptake sequence used is shown below, with the inverted repeats underlined in bold.
GGGCCCGGGCTGCAGCCGTCTGAAATGCATTTCAGACGGCTGCAGCCCGGGCCC
Transformation of N. meningitides.
N. meningitides grown overnight (37°C, S% COZ) on GC media (Difco) supplemented with 1 % Vitox (Oxoid), are gently resuspended in protease peptone broth ( 15 g/1 protease peptone No.3 (Difco), 4 g/1 KzHP04, 1 g/1 KH~P04, 5 g/1 NaCI, 1 % vitox) containing 10 mM
MgCl2 and diluted to an OD6~ of 0.2. 0.5 g of plasmid is added to 0.5 ml of resuspended bacteria and incubated (37°C, 5% COz) for 4 hours. 100 1 aliquots are plated out on selective plates (GC agar containing antibiotics, and any other nutritional supplements required; see table below). Plasmids used for transformation are suicide vectors with various selectable markers (see table) and a synthetic uptake sequence specifically required for natural transformation of Neisseria sp.
Table: Media supplements for selection of mutants Supplement Working conc. Use Chloramphenicol 12 g/ml Selection of cam containing mutants Erythromycin 5 g/ml Selection of ery containing mutants Kanamycin MIC* Selection of kan containing mutants Streptomycin 10 mg/ml Selection of streptomycin sensitive mutants Sucrose 15% Selection of SacRB deficient mutants Fe nitrate/sulphate 25 M Optional for furllac mutants IPTG 0.1 mM Optional for furllac mutants Diaminopimelic acid 100 g/ml Supplement for asd mutants *Minimum inhibitory concentration The final vaccine strain should preferably not contain any genes encoding antibiotic resistance. These genes are used as a marker of recombination events and may be removed by subsequent recombination.
Following introduction of the mutants into host bacteria the introduction may be confirmed by Southern blotting techniques under standard conditions, using the PCR amplified gene as a probe.
Example 1: aroB mutant (Figures 1 to 3) 1. Preliminary work It was hypothesised that the N meningitides aroB gene would be almost identical to the Ngonorrhoea aroB gene. Hence, the N.gonorrhoeae genome database was searched using the protein sequence from the E. coli aroB gene using tblastn. This located an open reading frame on Contig 306 (which recently evolved into Contig 310) encoding a very similar protein, a putative gonococcal aroB gene.
Based on the gonococcal Contig 306 sequence, primers AroB 1 and AroB2 were designed to PCR approximately lkb DNA upstream plus some of the beginning of the putative N.meningitidis aroB gene. Primers AroB3 and AroB4 were also designed to PCR
some of the end of the aroB gene and approximately 1 kb of downstream sequence.
Restriction sites were added so that the two PCR products could be cloned and joined to create a version of the aroB gene with the central portion of the gene missing. It was planned to replace the chromosomal meningococcal aroB gene with this deleted version using homologous recombination and so make an aroB mutant.
2. Cloning and sequencine of the putative menineococcal aroB gene Genomic DNA from a streptomycin resistant version of the N meningitides clone B16:B6 (Schryvers et aT, Microb. Pathog. 24, 75-87, 1998) was used for cloning the aroB
gene. PCR products AroBl-2 and AroB3-4 were generated using Taq and cloned into the pCRII vector (Invitrogen) for storage and sequencing. Resulting plasmids were labelled pCRI-2 and pCR3-4 respectively. Preliminary sequencing results (sequencing ends of PCR
products) confirmed they contained the target sequences.
3. Construction of suicide vectors for creating an aroB menin~ococcal mutant The suicide vectors are based on vector pGITS. This was derived from the pCRII
cloning vector {Invitrogen) but contains a deletion in the f3-lactamase gene for safety considerations and also a synthetic gonococcal uptake sequence cloned into the EcoRI site to guarantee uptake of the vector into Neisseriae species. In more detail, the ampicillin gene of pCRII was knocked out. A consensus DNA uptake sequence was synthesised based on Ngonorrhoea data (Burnstein et al, J. Gen. Microbiol. 134 (Pt. 3) 547-557, 1988: Stein, Can.
J. Microbiol. 37, 345-349, 1991 ). The uptake sequence was cloned into the EcoRI site of the pCRII.
The aroB deletion strategy involved two steps and used an erythromycin resistance (erythromycin R) cassette. Using a two-step process, the aroB gene could be replaced by the deleted version without leaving an antibiotic marker in the gene. The strategy did require a _28_ streptomycin-resistant N.meningitidis strain, however.
The first suicide vector contained the erythromycin R cassette sandwiched between the AroBl-2 and AroB3-4 PCR products. Firstly, AroB3-4 was legated between the KpnI and BamHI sites of pGITS to produce pGITSaroB3-4. AroB 1-2 was then legated between the KpnI and HindIII sites in pGITSaroB3-4 to make pGITSaroB O1-4. Finally, the erythromycin R cassette was inserted into the blunted KpnI site of pGITSaroB ~1-4 to produce pGITSaroB
Derm.
The second suicide vector is the same as the first, but omitting the erythromycin R
cassette. This had already been made and was pGITSaroB O1-4.
4 Interruption of the N.menin~itidis aroB gene using homologous recombination The streptomycin-resistant version of the Iv:meningitidis B16:B6 strain (B16B6strR) was transformed separately with two clones of the pGITSaroB germ vector and four erythromycin resistant clones picked and stored from each transformation (ie.
probably eight identical clones). All eight tranformants were erythromycin resistant and streptomycin sensitive. Hence, the pGITSaroB Derm cassette has almost certainly integrated into the bacterial chromosome. Kanamycin susceptibility was not tested, but would confirm the absence of the pGITS plasmid. The transformants have been cultivated on Blood Agar and GC agar plates on the assumption that both contain enough aromatic amino acids to overcome the attenuation of the predicted aro mutation. Minimum essential medium MEM
with agar (with and without Vitox) plus all the amino acids has been tested as a minimal medium, but none of the transformants grew and control strains did not grow well.
Example 2: asd mutant (Figure 4) A fragment comprising approximately 90% (1.3 kb) of the asd gene was amplified using PCR. Primers asdl and asd2 were designed by back-translation of the protein sequence based on the colon usage of N. meningitides. EcoRI sites were included at the 5' ends of the primers to facilitate cloning into the plasmid pUCl9. The resulting plasmid pASD-1 was sequenced to confirm the identity of the cloned fragment and to generate a restriction map.
Restriction sites were identified to create a deletion in the middle of the gene which also throws the latter part of the gene out of frame. The insert removed was a BcgI
fragment from positions 471-586 of the gene (where 1 is the A of the ATG start colon). This ensured complete inactivation of the gene product. A selectable marker cassette (comprising either CAT and SacRB genes which confer chloramphenicol resistance and sucrose sensitivity, or Erm and Rps 1 genes which confer erythromycin resistance and streptomycin sensitivity (Johnston, 1996, pages 37-38 in Abstracts of the 10"' International Pathogenic Neisseria Conference:
Sept. 8-13 1996, Baltimore, MD, USA; eds. Zollinger et al. )) was inserted at an NspI site of the undeleted asd gene (this occurs within the BcgI deletion site). This construct was then used to transform N.
meningitidis, with positive selection of mutants (resistance to chloramphenicol or erythromycin). Resistant colonies were then purified and transformed for a second time using the deletion construct devoid of any markers, with positive selection using either resistance to sucrose or streptomycin.
Mutants which have a mutation in the asd gene which encodes the essential cell wall enzyme -semialdehyde dehydrogenase can be identified by their requirement for diaminopimelic acid (DAP). Putative asd mutants were replica plated onto DAP-deficient and DAP-replete media. Those strains which grew on DAP-replete medium ( 100 g/ml) but not on DAP-deficient medium were asd mutants.
Example 3: ur construct (Fide 5~
For alterations in the fur gene it was essential not to have a complete knockout mutant since this may be lethal. Therefore the fur gene was placed under the control of another promoter which could be switched on or off independently of the factors (iron) which normally controls, fur expression.
Primers for the amplification of the entire fur gene were designed from the published sequence with an NdeI restriction site in the forward primer (primer furG) at the transcription start of the gene and a SalI restriction site in the reverse primer (primer furD) at the distal end of the fur gene. Primers furD and furG were used for the amplification of a 600 by fragment containing the entire fur coding sequence using PCR. The DNA fragment was polished with Pfu polymerase and cloned into the vector pCR-script (Stratagene), to give the plasmid pFUR-DG.
Primers for the amplification of a 300 by region upstream of the fur gene were designed with a BamHI restriction site in the reverse primer (primer furF), proximal to the transcription start and a San restriction site in the forward primer (primer furE), distal to the transcription start. The 300 by DNA fragment was cloned into the vector pCR-script as above to give the plasmid pFUR-EF.
Finally, two primers were designed and constructed to the IacZ promoter and repressor region (lacI) of the E. toll lac operon. The forward primer, lac 1, contained a BamHI site and the reverse primer, lac3, included the Iq mutation and an NdeI site which would regenerate the ATG transcription start when ligated to the NdeI site of the gene pFUR-DG
plasmid insert. The fragment generated using these primers was cloned into the vector pCRII
(Invitrogen), to give pLAC-13.
The Fur-EF fragment was removed from pFUR-EF by cutting with Sall and BamHl.
The Lac 13 fragment was removed from its vector with BamHI and NdeI. The Fur-DG fragment was removed from pFUR-DG by cutting with NdeI and SaII. These were sequentially ligated together to give the complete furllac construct in pUCl9. This was then sub-cloned into the pGITS suicide vector and inserted into the chromosomal location of the wild-type fur gene by allelic exchange.
In more detail, the,furllac construct was cut from the construction plasmid pUCl9-furllac using the enzyme SaIZ This was made blunt ended by filling the in 5' overhangs using klenow. The now blunted furllac fusion was cloned into the blunt EcoRV site of pGITS to give the plasmid pGITSfurllac. PGITSfurllac was transformed into the E.coli host DHSa. A 100 ml culture of DHSa (pGITSfurllac) in LB broth was grown up at 37°C to an OD6°~ = 0.7. This was used to carry out a large-scale plasmid preparation by the alkaline lysis method.
PGITSfurllac was introduced into the N meningitides strain B16:B6 as follows.
N meningitides strain B 16:B6 was grown in proteose-peptone broth at 37°C to an ODboo = 0.2.
These were pelleted by centrifugation and resuspended in an equal volume of proteose-peptone broth containing 10 mM MgCl2. To 250 p,l of bacterial suspension in a Bijou a maximum the pGITSfurllac was added to a final concentration of 1 ~,g/ml. This was incubated at 37°C for 4 hours in an atmosphere of 5% COZ in air with the lid of the culture vessel loose to allow COz entry. After this time the culture was plated onto GC agar plates and allowed to grow at 37°C in 5% C02 in air until colonies showed.
Colonies were replicated/transferred to nylon filters and colonies lysed by floating the membrane on a solution of 1% SDS. The plates were re-incubated to allow the colonies to grow up again. The DNA from the colonies on the membrane was denatured by floating on a 1N solution of NaOH and then neutralised by floating on 1 M Tris pH7Ø The filters were UV
irradiated to bind DNA to the membrane and then hybridised to a dig-labelled IacIR fragment prepared by a commercial kit (Promega). After hybridisation and extensive washing the membranes were developed using the solutions and protocol provided and N.
meningitides strains containing a IacIR fragment showed up as dark spots on the filter. The corresponding colonies were picked from the re-grown agar plates, grown up and stored.
Confirmation of the correct construct was carried out by PCR amplification of sequences from chromosomal DNA
using the fur and lac primers to confirm the presence of the fusion and its location. This will be confirmed by the Southern blots of restriction digests of chromosomal DNA.
One of the furllac strains were picked and grown for 12 hours in proteose peptone broth with varying concentrations of IPTG. Total proteins were prepared from the cultures by boiling in SDS-PAGE loading buffer (without the methylene blue dye). Lysates were dotted onto nitro-cellulose membranes and fixed in 1-% trichloro-acetic acid solution. The membranes were incubated for 1 hour with a i :1000 dilution of a rabbit polyclonal antibody to tranferrin binding proteins Tbpl and 2, in 50 mM Tris pH7.0 The membranes were washed extensively in 50 mM Tris pH7.0 and then incubated with a goat anti-rabbit secondary antibody, conjugated to alkaline phosphatase (Sigma), in 50 mM
Tris pH8.0 for 1 hour. After this time the membranes were washed in 50 mM Tris pH8.0 and developed in BCIP/NBT solution (available as tablets from Sigma). Binding of primary antibodies was seen as an intense blue/black staining in the region of the applied proteins, no antibody binding was seen as little or no colour development.
The results showed that the primary antibody to Tbp l and 2 bound more strongly to cells in the presence of IPTG than in the absence. Without IPTG there was very little binding of antibody (comparable to wild type in high iron conditions) indicating little expression of the fur/iron regulated Tbp 1 and 2. Whereas the concentration of IPTG was increased the binding of the primary antibody increased up to a level which appeared comparable to that seen with the wild type in low iron or iron free conditions. These results show that the furllac fusion strain does express its iron regulated proteins in response to IPTG. These data can be confirmed by Western blot analysis of total proteins and outer membrane proteins using various antibodies to iron regulated proteins. This could also be done for whole cells by colony blots and immunogold electron microscopy to confirm that the proteins are localised properly. Also, comparison of outer membrane profiles of iron-induced wild type IPTG induced fusion strains will show whether the profiles are similar.
Example 4: galEl mutant N. meningitides contains two chromosomal galE gene sequences, galEl and galE2 at separate loci. GalEl is complete, expressing a functional gene product, while galE2 is truncated and lacks homology over the first third of the protein. Primers galEA and galEB were designed to areas which are not conserved between galEl and galE2 to amplify a 1.5 kb fragment of galEl. A HindII site was engineered into each primer to facilitate cloning into pUCl9. After subcloning into the suicide vector pGITB (a pUC based vector with neisserial uptake sequence and lacking a BpmI site in the inactivated ampicillin gene, a selectable marker cassette (see Example 1 for alternatives) was inserted at a BpmI site (very close to the BcgI
deletion site). This construct was then used to transform N.meningitidis, and mutants identified by a chloramphenicol or erythromycin resistant phenotype. Resistant colonies were then purified and transformed for a second time using the GalEl BcgI deletion construct devoid of any markers, with positive selection using either resistance to sucrose or streptomycin.
To establish a change in LPS type, LPS is prepared from mutants and parental wild-type N.meningitidis by a proteinase K digestion of OMPs method and analysed on 15%
tricine SDS
PAGE gels. Bands are visualised by silver staining. LPS from galE mutants demonstrate greater electorphoretic mobility than their wild type parent strains.
Example 5: recA mutant.
DNA sequences of recA genes from various bacterial species were compared and primers recAl and recA2 were designed within conserved regions of the gene using the codon frequency of N. meningitides. The primers were designed with EcoRI restriction enzyme cleavage sites to facilitate cloning. The primers were used to amplify recA
from N. meningitides and the product was cloned into pUCl9. The resulting plasmid, pRECA-l, was partially sequenced to verify that the insert was from the recA gene and restriction mapped to identify useful restriction enzyme sites for the generation of the deletion derivative.
This deletion derivative, pRECA-D, was recombined into the wild type N. meningitides chromosome and the resulting strain was tested to determine its sensitivity to UV light compared to the parental strain.
UV sensitivity compared to the isogenic wild type strain can be determined by inoculating blood agar plates with parallel streaks of the wild type and the putative recA mutant.
The inoculated plates are exposed to known UV energy for increasing times. The plates are incubated at 37°C and S% COZ in air for 24 hours. UV sensitivity is shown by reduced growth of the putative mutant on plates compared to the adjacent wild-type strain. .
The strains obtained by this procedure are effectively isolated genetically and no further construction can be undertaken since they are now deficient in homologous recombination.
Example 6: DaroB. lac: fur fusion mutant The procedure of Example 3 is repeated, but this time using the attenuated N.
meningitides aroB mutant obtained by the procedure of Example 1. This provides an attenuated DaroB, laclfisr fusion mutant of N.meningitidis.
The invention further provides a process for preparing a vaccine composition comprising an attenuated bacterium according to the invention which process comprises (a) inoculating a culture vessel containing a nutrient medium suitable for growth of said bacterium;
(b) culturing said bacterium; (c) recovering bacteria from the culture and (d) mixing said bacteria with a pharmaceutically acceptable diluent or carrier.
The present invention also provides a method for producing a bacterium according to the invention which method comprises modifying the native fur gene, or homologue thereof, of an attenuated bacterium such that expression of said fur gene or homologue is regulated independently of the iron concentration in the environment of the bacterium.
Preferably, said bacterium has been attenuated by mutation of at least one gene essential for the production of a metabolite or catabolite not produced by a human or animal, more preferably by a mutation of an aro gene such as an aroB gene and/or aroL gene and/or a gene of the pur or pyr pathways, in particular a purE, purB, pyrA and/or pyrB gene.
Brief Description of the Drawings.
Figure 1 illustrates the construction of the suicide/transformation vector pGITS.
Figure 2 shows the primers used for the amplification of the aroB gene from Neisseria meningitides and construction of an aroB deletion mutant.
Figure 3 illustrates the construction of an aroB deletion mutant Figure 4 illustrates the construction of an asd mutant Figure 5 illustrates the production of a furllac fusion strain.
Detailed Description of the Invention.
The term "vaccine" as used herein means an agent used to stimulate the immune system of a vertebrate, particularly a warm-blooded vertebrate including humans, so as to provide protection against future harm by an organism against which the vaccine is directed. The immune system can provide two types of responses to foreign organisms - cell-mediated (T cell) and humoral (B cell/antibody) responses. Both types of responses can be stimulated by a _7_ suitable vaccine to produce a primary immune response which leads to the development of immunological memory, providing protection against a subsequent infection by a pathogen.
Stimulation of the cell-mediated immune system results in the development of naive T cells into effector T cells which are able to react much more quickly to future challenges. Stimulation of B cells of the humoral immune system leads to the production of antibodies, desirably neutralising antibodies/ bacteriocidal antibodies, directed to epitopes found on or in the attenuated bacterial strain. The antibody so produced may be any of the immunological classes, such as the immunoglobulins A, D, E, G or M. Vaccines which stimulate the production of IgA
are of particular interest since this is the principle immunoglobulin produced by the secretory system of warm-blooded animals, and the production of mucosal antibodies will help prevent infection or colonisation of the nasopharynx, which is one natural route of infection of bacteria including N. meningitides. However, this and other organisms may also be infectious via the bloodstream and thus an IgM and IgG response will also be desirable.
The bacterium of the invention may be in isolated form. This is usually desirable when the bacterium is to be used for the purposes of vaccination. The term "isolated" means that the bacterium is in a form in which it can be cultured, processed or otherwise used in a form in which it can be readily identified and in which it is substantially uncontaminated by other bacterial strains, for example non-attenuated parent strains or unrelated bacterial strains. The term "isolated bacterium" thus encompasses cultures of a bacterial mutant of the invention, for example in the form of colonies on a solid medium or in the form of a liquid culture, as well as frozen or dried preparations of the strains.
The term "mutation" and the like refers to a genetic lesion in a gene which alters the levels of expression of the gene or the activity of the gene product. Such a mutation may exert its effect on the levels of expression of a gene product at any stage from the level of transcription to the level of translation and protein stability.
Alternatively, a mutation may cause in a change in the coding sequence such that the resulting gene product has altered activity, generally reduced activity. For example, an "inactivating mutation"
would render the gene non-functional. The term "inactivating mutation" thus envisages deletion of the entire gene or substantial portions thereof, and also point mutations in the coding sequence which result in truncated gene products unable to carry out the normal function of the gene. Where deletion of a portion of a gene is carried out, it may be desirable to introduce frame shift mutations downstream of the deleted region to remove the possibility of small sections of the _g_ gene being expressed.
A mutation introduced into a bacterium of the invention will generally be a non-reverting attenuating mutation. Non-reverting means that for practical purposes the probability of the mutated gene being restored to its normal function is small, for example less than 1 in 106 such as less than 1 in 109 or even less than 1 in 10'Z. However despite this, it may be considered desirable that a bacterium for use as a live attenuated vaccine should carry at least two attenuating mutations. Usually these mutations will be in separate genes.
An "attenuating mutation" is a mutation in a gene which is required for the growth of a bacterium. Such a gene is thus usually a metabolic, for example a catabolic or biosynthetic, 1 o gene. Preferred attenuating mutations are made in genes which are required for the production of an essential nutrient or intermediate which is not available in the tissues of the human or animal host in which the bacterium is normally pathogenic. Thus the attenuated bacterium will not be able to simply obtain the essential nutrient or intermediate from the infected host.
A bacterium of the invention will be an attenuated form of a pathogenic bacterium. The term "pathogenic" means that the bacterium is capable of causing disease in a human or animal (especially avian or mammalian, including human) host, although in some cases the bacterium may be carried asymptomatically by healthy individuals. Examples of the latter type include N. meningitides and S. aureus.
Production of Bacteria The survival of any bacterium in a given environment depends on its ability to obtain all its growth requirements in competition with other resident organisms. It must express those proteins which are essential for growth and replication if it is to be competitive and survive.
Strains which carry a particular mutation or combination of mutations may be made from a species of bacteria in accordance with the present invention. These strains will carry particular genetic lesions or mutations which render the organism auxotrophic for an essential nutritional requirement. If the organism is unable to acquire this nutrient from its environment it will not proliferate and will die once endogenous levels are exhausted. If such mutations are incorporated into normally pathogenic bacteria and the essential nutrient or its intermediates are absent from the tissues of the host then that mutant organism will be attenuated and unable to establish a normal infection, if colonisation is a component of the infection process.
Bacterial strains according to the invention may be constructed using recombinant DNA
WO 98!56901 PCT/GB98/01683 _g_ methodology which is known per se. In general, bacterial genes may be mutated by a process of targeted homologous recombination in which a DNA construct containing a mutated form of the gene is introduced into a host bacterium which it is desired to attenuate.
The construct will recombine with the wild-type gene carried by the host and thus the mutated gene may be incorporated into the host genome to provide a bacterium of the present invention which may then be isolated.
Various assays are available to detect successful recombination. In the case of attenuations which mutate a target gene necessary for the production of an essential metabolite or catabolite compound, selection may be carried out by (i) screening for bacteria unable to grow in the absence of such a compound; (ii) genetic methods to determine the deletion of the gene and/or (iii) showing that a genetically determined mutant can not grow in human fluids, for example blood or cerebrospinal fluid.
The mutated gene may be obtained by cloning the wild-type gene from the bacteria which is to be attenuated, or from a closely related species, and manipulating it by standard recombinant DNA techniques. These include introducing deletions into the gene, e.g. by digesting with a restriction enzyme which cuts the coding sequence twice to excise a portion of the gene and then religating under conditions in which the excised portion is not reintroduced into the cut gene. Alternatively frame shift mutations, which alter the reading frame of the DNA sequence, may be introduced by cutting with a restriction enzyme which leaves overhanging 5' and 3' termini, filling in and/or trimming back the overhangs, and religating.
Similar mutations may be made by site directed mutagenesis. These are only examples of the types of techniques which will readily be at the disposal of those of skill in the art. Another example is PCR of flanking regions adjacent to the target gene followed by ligation to form a deletion mutation construct.
The cloning of the wild-type gene may be undertaken using PCR cloning methods which are also known per se in the art. Such methods require knowledge of at least part of the sequence of the gene which is to be mutated. The sequence may be obtained by reference to databases such as Genbank. Where a gene sequence is not known for a particular organism, consensus sequences may be determined by aligning sequences of corresponding genes of other, related, organisms and determining regions which are most conserved. For example, the aro, pur and pyr genes of N.meningitidis can be isolated by screening the N.gonorrhoea raw database for sequences that have similarity to E.coli proteins. The appropriate gene sequences can be identified and primers designed for amplification of the corresponding genes of N.meningitidis. In general, many genes, especially those of metabolic and catabolic pathways are well conserved between gram-negative bacteria and appropriate PCR primers can be determined without difficulty.
The above techniques are exemplified further in the Examples below and can be readily adapted to provide other embodiments of the invention. Reference may also be made to, for example, Sambrook et al., "Molecular Cloning - A Laboratory Manual" (Cold Spring Harbor, 1989) or "Short Protocols in Molecular Biology - A Compendium of Methods from Currrent Protocols in Molecular Biology" eds. Ausubel et al. (John Wiley & Sons, 1992).
Attenuating Mutations.
An attenuating mutation can, for example, be made in a gene encoding a component of a metabolic pathway so that the growth of the attenuated bacterium is inhibited due to a lack of an essential metabolic intermediate of a particular metabolic pathway. Growth of such attenuated bacteria can then be achieved in culture by supplying the essential metabolic intermediate in the culture medium. However, when such attenuated bacteria are administered to a human or animal host for vaccination purposes, it is clearly desirable that the host itself is not able to supply the essential metabolic intermediate required by the attenuated bacterium for optimum growth. Consequently, attenuating mutations are preferably made in genes essential for the production of a metabolite, for example an anabolite or catabolite, not available in the human or animal host which is to be vaccinated.
Particular examples of pathways whose genetic components may be inactivated by mutation include 1. aromatic amino acid biosynthetic pathways, 2. purine biosynthetic pathways and 3. pyrimidine biosynthetic pathways.
1. Aromatic ring~biosynthetic pathways - The shikimic acid pathway This pathway is involved in the biosynthesis of virtually all aromatic compounds but is not present in mammals. It is therefore particularly preferred that mutations are made in genes encoding components of this pathway. The enzymes catalysing the various reactions of the shikimic acid pathway (and their corresponding genes) include 3-dehydroquinate synthase (aroB), 3-dehydroquinate dehydratase (aroD), shikimate dehydrogenase (aroE), shikimic acid kinase I (aroK), shikimic acid kinase II (aroL), 5-enoylpyruvyl shikimic acid 3-phosphate (aroA) and chorismate synthase (aroC).
A lesion in any of the genes of the shikimic acid pathway would render the bacterium auxotrophic for the essential nutrient chorismate. If the lesion occurs in a gene of the pathway prior to shikimic acid kinase I (aroK) but not in any of the downstream genes the bacterium will also be auxotrophic for the essential nutrient shikimate. Since these compounds are essential for aromatic amino acid biosynthesis in gram-negative and some gram-positive organisms and are absent from mammalian or other vertebrate tissues, mutants would undergo lysis after about three rounds of division in such tissues. Such a mutation will limit the proliferation of the bacteria in host tissues but will not affect their growth during vaccine production since the essential nutrients or aromatic amino acids can be provided exogenously during bulk culture of the vaccine strain.
The invention provides, in a particularly preferred embodiment, a live attenuated vaccine which is effectively attenuated by construction of specific deletion and frame-shift mutations initially in the aroB gene. The Neisseria gonorrhoeae aroB gene has been cloned and its nucleotide sequence deposited in Genbank as Accession No. AJ002783.
It is also particularly preferred that an attenuated bacterium of the invention has an inactivating mutation in the aroL gene, in addition to or instead of an inactivating mutation in the aroB gene. The E. coli aroL gene is described in Biochem J. (1986) 237(2):
{Genbank Accession No. X04064).
Functional inactivation of the aroA gene is preferably a secondary mutation once a primary mutation in one of the other aro genes (or one of the other genes described below) has been carried out. The E. coli aroA gene is described in FEBS Lett. (1984) 170:
59-63 (Genbank Accession No. X00557).
Mutations in aroC and aroD have been described in EP-A-322 237. The E.coli aroC
gene is described in Biochem J. (1988) 251(2): 313-322 (Genbank Accession No.
Y00720).
The Neisseria gonorrhoeae aroD gene is described in Mol. Gen. Genet. ( 1997) 254(5): 479-485 (Genbank Accession No. U39803). The Neisseria meningitides aroE gene is described in Mol.
Microbiol. 23(4): 799-812 (1997) (Genbank Accession No. U82841).
2. Purine biosynthetic~athways Mutations in any of the genes in the pur pathway (e.g. purB (encoding adenylosuccinate lyase) or purE (encoding 5'-phosphoribosyl-5-amino-4-imidazole carboxylase)) will render the organism auxotrophic for purines, essential constituents of nucleic acids.
Many of the intermediates of the pathway are unavailable in mammalian or other vertebrate tissues.
3. Pyrimidine biosynthetic pathways Mutations in any of the genes in the pyr pathway (e.g. pyrA (encoding carbamyl phosphate synthetase) or pyrB (encoding aspartate transcarbamylase)) will render the organism auxotrophic for pyrimidines, essential constituents of nucleic acids. Many of the intermediates of the pathway are unavailable in mammalian or other vertebrate tissues.
Other genes which may be mutated include the asd gene which encodes aspartate-semilaldehyde dehydrogenase. Mutations in asd would not be made as a primary mutation and would instead be made subsequent to a primary mutation in one of the other genes described above. The N. rneninigitidis asd gene is described in Gene (1993) 129(1): 123-128 (Genbank Accession No. Z14063).
Inactivating mutations may be made in only one of the genes described above (or another suitable gene) or alternatively, mutations in multiple genes may be employed, for example with mutations in the aroB gene as the primary mutation followed by mutations in at least one of the other genes. A double or triple mutant may be useful from the safety point of view since it will be more attenuated, but such a double mutant may also be less efficient as a vaccine. Strains with different levels of attenuation may be assessed during trials for their degree of efficacy and any side effects. Mutations of any of these genes may be accomplished, for example, in a similar way to that described for aroB in the Examples.
Mutation to maximise exposure of important epitopes The galE gene codes for UDP-galactose-4-epimerase. In Neisseria this enzyme does not appear to have a role as part of the galactose biosynthesis pathway, but it is involved in the incorporation of galactose into the phase-variable oligosaccharide side chains of LPS/LOS. N.
meningitidis contains two chromosomal galE sequences, galEl and galE2 at separate loci.
GalEl is complete, expressing a functional gene product, while galE2 is truncated, and lacks homology over the first third of the protein. The galE gene and its role in biosynthesis of LOS/LPS is described in Molecular Microbiology (1993) 10: 361:369.
A mutation in the galE gene denudes and shortens the LPS of galactose residues. Thus, a galE deletion exposes the constant region of the LPS to the immune system.
which leads to the generation of a cross-protective response. The reduction in the length of LPS may reduce the capsule on the surface of the organism. A further effect of a galE
mutation and the resulting short LPS is that outer membrane proteins exposed on the cell surface will become more accessible to the hosts immune system potentially leading to an improved immune response to the vaccine strain. Thus incorporation of a galE mutation, rendering the gene non-functional, into a Neisseria strain of the invention is preferred.
In addition, without the incorporation of galactose into the LPS the potential autoantibody-producing epitopes of LPS will not be incorporated. These epitopes are normally found on host epithelial cells and in many host secretions. Thus their removal from vaccine strains will greatly reduce the danger of immunopathological effects of the vaccine.
It has also been shown in bacteria, particularly N. meningitides, that the galE mutation results in an increase in opc-mediated invasion. For a vaccine intended for nasal delivery, this may be advantageous in stimulating the initial host tissue response and subsequent mucosal immunity, while other mutations (such as in the aroB gene) V~rould limit the proliferation of invading bacteria to approximately three rounds of division, precluding the possibility of a systemic infection. Aiso there is some evidence that galE mutants are serum sensitive and therefore would be rapidly killed if they entered the hosts circulatory system.
A mutation in a capsule gene, cap, may also result in increased exposure of epitopes.
That may in turn result in an increased immune response to the attenuated baterium.
Invasion/adhesion.
A galE mutation will expose the Opc protein thus making the vaccine strain able to colonise and invade into the blood stream more efficiently. This would be important to get a good mucosal and serum immune response in the limited time that the strains survive in the human body. There are two possible modifications to opc that may be made in accordance with one embodiment of the invention.
If there is excessive adhesion or invasion with the vaccine strain, then opc expression may be modified or even eliminated entirely. Where opc expression is found to be important for vaccine efficacy but is variable in expression, then opc may be placed under the control of another promoter e.g. cat, which can be more readily controlled. The opc opacity protein may be found by reference to the EMBL/GenBank/DDBJ databases. 1993. Accession number Z 14063 (Microb. Pathog ( 1991 ) 11:249-257).
Mimicking in vivo expression of iron re;,ulated proteins One failing of live attenuated vaccines in the past has been that during bulk culture the organism has not expressed some proteins which are important for host protection. Such proteins include iron regulated proteins, the production of which is regulated by the fur (ferric uptake regulation) gene. In addition, once such vaccines have been administered to the host, the vaccine strain has not had time or metabolic resources during its limited colonisation to express these proteins in vivo.
To overcome these problems, the present invention provides vaccine strains which have been modified such that many of the proteins which are likely to be important immunogens, e.g.
the iron regulated proteins, are already expressed on the cell surface during bulk culture. This is achieved by altering the regulation of the ferric uptake regulation (fur) gene (EMBL/GenBank/DDBJ databases. 1993. Accession number L19777, Mol. Microbiol (1994) 11(4): 725-737 (Neisseria); Mol. Gen. Genetics (1985) 200: 110-113 (E coli)).
The fur gene may be modified to produce its gene product independently of the iron concentration in the environment of the bacteria by any suitable means. In this context, the term "gene" is intended to encompass both the coding sequence of the fur protein together with any transcriptional/translation control sequences present, including promoters, transcriptional stop sequences, ribosome binding regions and other translation regulation elements.
Thus, modifications may be made to the coding sequence and/or the transcriptional/translation control sequences. For example, the promoter sequences of the gene may be determined (e.g. by reference to the database sequence and/or sequencing this region using PCR
primers directed upstream from the coding region) and the promoter regions responsible for iron concentration-dependent regulation may be modified by mutation, including deletion, insertion and/or substitution. One such identified promoter region is the fur box. Since fur expression may be required for positive regulation of some essential genes in Neisseriacae and complete inactivation of the fur gene is often lethal to the bacterium, the minimum levels of expression from the modified fur gene will preferably be sufficient to allow viable growth of the bacterium.
In particular, levels of expression from the modified fur gene are preferably at least equal to those obtained using the native fur gene in the presence of low levels of ferric ions, i.e. the maximal repressed state.
Alternatively the endogenous fur gene may be placed under the control of another promoter entirely. Such a heterologous promoter may be any promoter which is regulated independently of iron concentration and which functions in the host bacterium.
Preferably said promoter comprises a bacterial promoter such as a promoter derived from that bacterium or a member of the same family, or from a bacteriophage. Suitable promoters include both constitutive promoters such as that of the chloramphenicol resistance gene and regulatable promoters such as the promoters of catabolic, metabolic and biosynthetic genes, including those involved in the regulation of amino acid biosynthesis (which are induced when a required amino acid is absent or at a low concentration) or those involved in the metabolism of sugars (which are induced by the presence of the appropriate sugar). The trp promoter and the IacZ promoter are particular examples of the above, and the latter is especially preferred.
The promoter region of the endogenous fur gene is conveniently modified by homologous recombination with a suitable construct. The construct may comprise all or part of the fur gene together with the desired replacement promoter sequences provided that recombination results in modification of the endogenous fur gene.
Alternatively, the endogenous fur gene may be inactivated, and a complete fur gene together with the desired replacement promoter sequences introduced into the bacterial genome or maintained as an extrachromosomal plasmid. This will ensure that even in the presence of iron tittle fur gene expression occurs, although the heterologous promoter wilt allow sufficient expression of any essential genes positively regulated by fur.
In a particularly preferred embodiment of the invention, to overcome the problems of regulating fur and also to mimic in vivo levels of expression of iron regulated genes, fur gene expression is placed under the control of the IacZ promoter/lacl repressor which confers positive regulation of -galactosidase in the presence of lactose. Preferably, the 19 mutation in lacl is included which increases the basal level of expression ten-fold. This provides for sufficient production of fur to allow expression of essential genes and also allows the control of fur expression to be regulated in response to intracellular lactose concentrations.
Mutations may also be made in the coding sequence of the fur gene, which encodes the fur protein. By way of example, a mutation can be made which modulates the affinity of the fur protein for ferric ions. Preferably, such a mutation would abolish or substantially reduce the affinity of the fur protein for ferric ions. In this way, the fur proteins transcriptional regulatory functions would be independent of the iron concentration in the environment of the bacterium.
WO 98!56901 PCT/GB98/01683 Preferably, an attenuated asd mutant is used and its fur gene replaced with a fur gene under the control of the lacZ promoter/lacl repressor. The resulting low levels of the fur protein would enable the negatively regulated fur-controlled genes to be switched on, mimicking iron restricted conditions. The strain would therefore be fully attenuated but would fully express all iron-regulated proteins before being administered to the recipient without the need for iron-restricted growth conditions. The host would then be able to mount an immune response that would mimic that in response to the wild-type pathogen.
Thus placing fur under the regulation of the lacZ promoter is preferred. This allows its expression only in the presence of lactose or one of the non-metabolisable lactose analogues such as IPTG. Since the lac inducer dissociates from the lac operator in the presence of lactose, fur expression can be reduced down to basal levels by growing the strain in the absence of lactose. This effectively up-regulates all fur regulated genes mimicking growth in low iron, in vivo conditions. The result will be that in the absence of lactose, the bacteria will respond as if they are experiencing iron restricted conditions, producing the iron regulated proteins normally expressed in vivo, without the use of large quantities of iron chelators. It is thus possible to control fur expression independent of the iron concentration in the medium.
Fur expression will only be at "trickle through" basal levels in the absence of lactose. The maintenance of this basal level of expression is thought to be important for cell viability.
Therefore, in this embodiment of the invention, when the vaccine is administered to the host, many of the important proteins will already be present on the bacterial surface. This will relieve the metabolic burden that the bacterium will experience in vivo, freeing the resources of the bacterium to express other in vivo regulated proteins which are not iron regulated but are important for host protection.
The production of attenuated strains of bacteria in which the expression of fur has been modified as described above is a generally applicable technique. Thus any normally pathogenic bacterium which has a genome comprising a fur gene or homologue thereof, which bacteria is attenuated by deletion or modification of a gene essential for growth in a host in which the bacteria is pathogenic, may be modified as described above so that it produces the fur gene product, or homologue thereof, independently of the iron concentration in the environment of the bacteria. Fur homologues can be identified by sequence comparison with other known fur gene sequences from, for example E. coli and N. meningitides. Preferably, such homologues are substantially homologous to another known fur gene. In particular it is preferred that homologues have sequence identity of at least 60% at the amino acid level, more preferably 70%, over a stretch of at least 100 amino acids. Fur homologues can also be identified on the basis of function. The product of the fur gene in Neisseria controls the expression of numerous genes including those encoding toxins and iron uptake components, and is responsive to ferric ion concentrations. Thus genes identified in other bacteria which encode transcription factors which also have these ferric iron-responsive properties may be used.
Mutations to achieve genetic isolation and stability.
Another consideration of live attenuated vaccines which has to be addressed is the genetic stability of the strain. The strain must not be able to revert to a wild-type phenotype, nor must it lose the ability to express genes important for host protection.
Genetic stability can be increased by introducing a deletion in the recA gene. This gene enables the organism to repair its DNA by homologous recombination. The recA mutation knocks out homologous recombination - the process which is exploited for the construction of the mutations. Once the recA mutation has been incorporated the strain will be unable to repair the constructed deletion mutations. A mutation in recA will also make the strain sensitive to ultra-violet light and will be an important containment factor.
In addition, it would prevent the strain from repairing the genetic lesions by homologous recombination using wild-type DNA found in the environment or the tissues of the host (commensal Neisseria for example). A recA mutation also increases the general stability of the strain by reducing the loss of phenotypic characteristics by deletions and inversions which are mediated at least in part by such recombination pathways. RecA genes have been widely studied in the art and their sequences are available. Reference may be made to EMBL/GenBanklDDBJ databases. 1992. ID code NM446REC (or Molecular Microbiology ( 1992) 6:213 S-2146).
In many cloning procedures, selectable markers are used to select desired mutants.
However, it may be preferred to remove subsequently the selectable marker.
Since introducing a recA mutation will disable the recombination apparatus of the bacterium it will not be possible to use a subsequent recA-dependent recombination event to remove the selectable marker. Thus a particularly preferred method for introducing a recA mutation which allows subsequent removal of a selectable marker is to flank the selectable marker sequences with sequences which are recognised by a recombinase/resolve-type enzyme. For example, the product of the parA
gene is a resolvase that specifically excises regions of chromosomal DNA
flanked by 140 by res sites (J. Bact. (1995) 177:52-58). Therefore the recA mutation cassette may comprise a selectable marker gene flanked by res sites. Once mutant bacteria with the desired recA
mutation have been selected, introduction of a plasmid encoding the parA
resolvase will result in excision of the selectable marker gene. Plasmid RP4 (J. Bact. (1995) 177:52-58) is an example of such a plasmid. Expression of the resolvase protein even at low efficiency will be sufficient to result in the excision of the selectable marker gene flanked by the res sites. The plasmid bearing the parA gene lacks a Neisserial origin of replication and would be lost naturally from Neisseria sp.
Additional genetic stability.
Once the recA activity has been abolished, the bacterial strain may still have some residual ability to take up exogenous DNA. This may vary from strain to strain. If the frequency of such events is considered too high (e.g. by regulatory authorities) a further mutation may be introduced to reduce DNA uptake. Such a mutation may be made in any gene involved in DNA uptake and would be made in a particular strain prior to the mutation of recA
if it is found that the recA mutation alone is not sufficient.
The comA gene of N. gonorrhoeae is involved in competence. A mutation in the comA
locus would render this organism unable to take up exogenously added DNA, making the strain genetically isolated, biosafe and more stable. Corresponding mutations at homologous loci may be made in N meningitides and other organisms. Those of skill in the art will appreciate that it will be necessary to recombine the recA and comA (or other gene involved in DNA uptake) constructs simultaneously, since both recombination and competence functions to introduce these lesions. Thus where a recA and/or comA lesion is required in a strain, this/these will be introduced as the final genetic modification, following the other modifications described herein.
RTX toxin.
The N. meningitides vaccine strains produced in accordance with the embodiments of the invention described above will still express the genes for the RTX toxin and its secretion machinery (encoded by frp locus). The outer membrane proteins for toxin secretion may be important protective antigens. However, the toxin itself, which is iron regulated, may cause some adverse reactions, for example in some subgroups of patients or with some attenuated strains. If the production of the RTX toxin causes problems during the limited colonisation of the vaccine strain, then the toxin gene will be inactivated by defined deletion or other modification. This will leave the genes for the outer membrane transport proteins intact, since they may be important elements for the efficacy of the vaccine.
One option would be to inactivate the toxin structural gene (frpA) by the insertion of a SacRB cartridge from B. subtilis . This would result in a sucrose sensitive phenotype which would provide a molecular tag, allowing genetic stability to be monitored during manufacture.
The RTX toxin gene may be found by reference to Mol. Micro (1993) 9:85-96.
Although an RTX mutation is envisaged primarily with reference to N.
meningitides, many other bacteria have a similar RTX toxin and corresponding mutations may be made in these. In addition, other bacteria produce other types of toxin and it may be necessary to introduce mutations into the genes encoding these toxins, using standard techniques.
Membrane Vesicles.
In addition to the live attenuated vaccine, membrane vesicles derived from this N. meningitides or other vesicle-producing bacteria may be a better option for certain patients or patient groups. N. meningitides and other bacteria naturally produce membrane vesicles which may be isolated. These may be used directly to induce a strong immune response.
Mutations in the E. coli mina locus (see Eur. J. Biochem. (1981) 116:331-335) cause aberrant cell division and the production of mini DNA-less cells. Mutations in this locus and homologous loci in other bacteria will greatly increase the production of membrane vesicles or mini cells by these bacteria. Thus the present invention also provides a bacterium with additional mutations in loci homologous to the E. coli mina locus (described in Cell (1989) 56:
641-649 - Genbank Accession No. J03153).
Strains of N. meningitides.
To provide attenuated strains of N. meningitides any suitable starting strain may be used.
In general, clinical isolates are preferred since these represent strains which have been shown to cause disease in patients. Clinical isolates include KH 454 Serotype B 15 P
1.7 (J. Med.
Microbiol. (1995) 42:353-361), nm3474 Serotype B2B P1.10 {available from Nottingham Public Health Laboratory Service, Nottingham, UK) and strain B 16:B6 (Schryvers et al, Microb. Pathog. 24, 75-87, 1998). However these are only examples and many clinical isolates are available in medical microbiology laboratories throughout the world.
Whatever starting strain is used, preferred genotypes of attenuated strains in accordance with the invention include the following:
1. aroB, galE, lac:fur fusion, recA.
2. aroL, galE, lac. fur fusion, recA.
In either case one or more of the following characteristics are additionally preferred:
i) a mutation in a homologue of mina ii) an RTX negative phenotype; and iii) an opc gene, the expression of which has been modified or eliminated.
iv) a mutation in a capsule gene.
l~~ menin~itidis as a carrier for other antigens.
Attenuated strains of the invention will also be useful as a vehicle for the delivery of other antigens from other pathogens, including viral and bacterial pathogens.
This will be useful where protection against such other pathogens can be obtained by stimulation of the immune system by such an antigen. Examples of this include the hepatitis B
surface antigen, pertussis toxin, V. cholerae or ETEC B subunit toxin or diphtheria toxin.
In these cases a gene encoding the antigen will be operably linked to a promoter capable of functioning in the bacterium of the invention to provide an expression cassette or vector and such a cassette or vector will be introduced into the bacterium. The cassette or vector may also comprise genomic sequences from said bacterium to allow for homologous recombination of the cassette or vector into the genome of the cell. For example, the cassette or vector may be designed such that the antigen gene replaces one of the genes described above which is to be attenuated.
Growth of strains and production of vaccines.
Once bacteria have been engineered in accordance with the invention, they may be grown in culture and the culture recovered to provide bacteria for a vaccine composition.
Conditions for the growth of bacteria are well known in the art, and industrial processes for recovery of bacteria are also widely available.
Vaccine preparations.
The bacteria of the invention, or the membrane vesicles, may be formulated into vaccine preparations. Typically vaccines are prepared by mixing the bacteria with a pharmaceutically acceptable carrier or diluent. Such carriers or diluents include water, saline, dextrose, trehalose, glycerol, ethanol or the like, or mixtures thereof. The vaccines may comprise one bacterial strain or a mixture of strains (i.e. either a mixture of different types of the same species and/or different species).
The concentration of the attenuated strain in the vaccine will be formulated to allow convenient unit dosage forms to be prepared. Concentrations of from about 10° to 109 bacteria per ml will generally be suitable, e.g. from about 1 OS to 1 O$ such as about 1 O6 per ml. Where membrane vesicles are formulated, suitable concentrations will be in the range of from about I
to 100, e.g. 5 to 50 mg of protein per ml.
The vaccine composition may, for example, be formulated as an aerosol, particularly for N. meningitides, at concentrations the same as those described above and as a preparation for injection.
Administration of vaccines.
The vaccines of the invention may be administered to recipients in order to protect them against diseases caused by the corresponding wild type organism. Although human recipients are primarily envisaged - especially for N. meningitides which causes disease in humans vaccines of the invention will have veterinary uses, for example in vaccinating domestic pets such as cats and dogs, and in vaccinating livestock such as mammals including cattle, sheep and swine or other vertebrates such as poultry. These animals may be vaccinated in particular with attenuated enteric bacteria of the invention.
The vaccine may be administered by any suitable route. In general, subcutaneous or intramuscuiar injection is most convenient. This will lead predominately to a serum immune response which should prevent dissemination of the organism, throughout the body and the resulting septicaemia Because it is unknown whether this route of administration will provide any protection against colonisation of the nasopharynx and carriage, vaccinations against bacteria which also invade through this route may also be by use of an intranasal spray. This will lead to colonisation of the nasopharynx mimicking closely the natural route of infection and carriage.
The expected immune responses will be (a) mucosal - which would generate mucosal antibodies and should prevent colonisation by pathogenic bacteria and (b) serum - which should prevent dissemination of the bacteria throughout the body and the resulting septicaemia. This route of administration is particularly preferred for vaccination with attenuated strains of N. meningitides.
Indeed, for N. meningitides it is intended that this vaccine strain will primarily be delivered as a nasal aerosol, allowing the strain to colonise the nasopharynx (the initial site of colonisation for the wild-type organism). Due to the aro and the galE
mutations the strain will exhibit a limited invasion of the tissues and possibly entry into the blood stream before viability is lost through serum killing and autolysis. This will mimic closely the progression of the natural route of infection, producing mucosal and serum immunity. This may be boosted if desired by injection.
For infants where there may be some reluctance to vaccinate with a live attenuated vaccine, non-viable membrane vesicles may be used. As described above, such vesicles are naturally produced by lV. rneningitidis and can be harvested as a vaccine to be administered subcutaneously, intramuscularly or by nasal aerosol.
Doses of vaccine will ultimately be at the discretion of the physician, taking into consideration the status (e.g. age, weight, disease status) of the recipient and the nature of the vaccine strain used. However some general guidance may be found by reference to the published literature.
For example, intranasal doses of N. meningitides may be calculated by reference to animal models such as those disclosed in Microbial Pathogenesis (1992) 12:415-420 or Canadian Journal of Microbiology (1984) 30:1022-1029. Suitable intranasal doses are around 105 to 108, e.g. about 106 or 10' organisms in a single dose.
Live attenuated organisms may be administered subcutaneously or intramuscularly at up to 108 organisms in one or more doses, e.g. from around 105 to 108, e.g. about 106 or 10' organisms in a single dose.
Membrane vesicles may also be administered subcutaneously, intramuscularly or nasally in an amount of about 25-100 mg of protein (depending on LPS content of vesicles) in 2-3 doses. (See for example Infection and Immunity (1996) 64:2745-2751, Infection and Immunity (1995) 63:4642-4652 or Infection and Immunity (1995) 63:3531-3536).
The recipient may receive one or more doses, in the latter case the doses may be repeated at an interval of from one week to one or more months, e.g. 2, 3, 6, 12, 18 or 24 months.
The above doses are provided primarily with reference to adult humans. They may be scaled up or down in proportion to body weight for non-adults or for other species.
The invention will be described with reference to the following Examples, which are intended to be illustrative only and non-limiting.
EXAMPLES
Materials and Methods Gene construction The following PCR primers were synthesised for use in the genetic construction of vaccine strains. The primers were designed to contain a restriction site for ease of manipulation of the amplified products.
PRIMERS
Name - Gene - Sequence - Direction - Enzyme T G
aro 1 - aroA - GGAATTCGATTCCGATGATATCCGTCATATG - forward - EcoRl CAG C CG G C C
C
Aro2 - aroA - GGAATTCATCAGGAATATGATTCATATCCAT - reverse - EcoRl G G G G G G
AroB 1 - aroB - GCAGATGCCCGAAGCTTTTTATAGCGG
AroB2 - aroB - GAGCTCGGTACCGTGCAGCGTGTCCAGATCTGCAAG
AroB3 - aroB - CATAAAGGGATCCTGGTTCGCCAG
AroB4 - aroB - GGTACCGAGCTCCAAATGAAGGCAGATCTCGTCGCCC
AsdA - asd - ACAATGAAAGTAGAATTCGTCGGCTGG - forward - EcoRl C
AsdB - asd - GAATGCGGAGATGAATTCGCCGCCCAT - reverse - EcoRl G C T
FurD - fur - CCCTGCTCACGTCGACCAG - reverse - SaII
FurE - fur - ACGCGGTCGACGCTGCACG - forward - SaII
FurF fur -AATACGCAATTGGATCCTGCTTGC - reverse - BamHI
FurG - fur - GATATTGAATCATATGGAA.AAATTC - forward - NdeI
galEA - galEl - GTGATTTTGGATAAGCTTTGCAATTCC - forward - HindIII
galEB - galEl - CCAGCGCCATGAAGCTTCCATCAT - reverse - HindIII
lacl - lacl - GACAGGATCCAATGGTGCAAAACC - forward - BamHI
lac3 - lacZ - AATCATGGTCATATGTGTTTCCTG - reverse - NdeI
recAl - recA - CGGAATTCGGTCTGAAGCGGATG - forward - EcoRI
recA2 - recA - CGCAGCAGGAATTCCCGTTTATCG - reverse - EcoRI
These primers were used for amplifying target DNA to obtain copies of wild-type genes from target starting strains of bacteria. To obtain target DNA, 80 ml of overnight culture were grown in broth and harvested in 2 x 50 ml polypropylene tubes. The bacteria were recovered and DNA obtained using a standard phenol-chloroform extraction protocol.
Target genes were amplified by PCR under appropriate conditions carried out for 35 cycles, with the final cycle having an extension at 72°C for 9.9 minutes so that all extensions are completed. The purity, size and amount or PCR product obtained from any amplification is determined simply by agarose gel electrophoresis. 10 1 of the PCR reaction are analysed by agarose gel electrophoresis on a 1 % agarose gel and different size DNA
fragments separated and identified under UV light by staining with ethidium bromide. The size of the amplified DNA fragment was determined by comparison with known size markers. The amplified product was cloned into one of a range of vectors including pUC 19, pCRII, PCRscript and pSP72.
The above techniques may all be found in standard reference books such as Sambrook et al.., Cold Spring Harbor, 1989.
Mutants were constructed in vitro by identifying restriction enzyme sites from the information obtained by the sequencing of the cloned PCR product. Once restriction sites) in the desired areas) are identified, the cloned fragment is cut with the appropriate enzyme(s), removing a fragment from the centre of the cloned insert. 1'he plasmid is then re-legated and deletion derivatives identified by the reduction in size on agarose gels and by sequencing. This procedure is used to develop defined mutations in the genes aroA, galE, asd and recA.
Vectors Vectors used for transformation of N. meningitides include uptake sequences to assist with uptake of the vector by the bacterium. These sequences comprise a 10-mer inverted repeat (Goodman and Socca, Proc. Natl. Acad. Sci. (1988) 85:6982-6986). The nucleotide sequence of the uptake sequence used is shown below, with the inverted repeats underlined in bold.
GGGCCCGGGCTGCAGCCGTCTGAAATGCATTTCAGACGGCTGCAGCCCGGGCCC
Transformation of N. meningitides.
N. meningitides grown overnight (37°C, S% COZ) on GC media (Difco) supplemented with 1 % Vitox (Oxoid), are gently resuspended in protease peptone broth ( 15 g/1 protease peptone No.3 (Difco), 4 g/1 KzHP04, 1 g/1 KH~P04, 5 g/1 NaCI, 1 % vitox) containing 10 mM
MgCl2 and diluted to an OD6~ of 0.2. 0.5 g of plasmid is added to 0.5 ml of resuspended bacteria and incubated (37°C, 5% COz) for 4 hours. 100 1 aliquots are plated out on selective plates (GC agar containing antibiotics, and any other nutritional supplements required; see table below). Plasmids used for transformation are suicide vectors with various selectable markers (see table) and a synthetic uptake sequence specifically required for natural transformation of Neisseria sp.
Table: Media supplements for selection of mutants Supplement Working conc. Use Chloramphenicol 12 g/ml Selection of cam containing mutants Erythromycin 5 g/ml Selection of ery containing mutants Kanamycin MIC* Selection of kan containing mutants Streptomycin 10 mg/ml Selection of streptomycin sensitive mutants Sucrose 15% Selection of SacRB deficient mutants Fe nitrate/sulphate 25 M Optional for furllac mutants IPTG 0.1 mM Optional for furllac mutants Diaminopimelic acid 100 g/ml Supplement for asd mutants *Minimum inhibitory concentration The final vaccine strain should preferably not contain any genes encoding antibiotic resistance. These genes are used as a marker of recombination events and may be removed by subsequent recombination.
Following introduction of the mutants into host bacteria the introduction may be confirmed by Southern blotting techniques under standard conditions, using the PCR amplified gene as a probe.
Example 1: aroB mutant (Figures 1 to 3) 1. Preliminary work It was hypothesised that the N meningitides aroB gene would be almost identical to the Ngonorrhoea aroB gene. Hence, the N.gonorrhoeae genome database was searched using the protein sequence from the E. coli aroB gene using tblastn. This located an open reading frame on Contig 306 (which recently evolved into Contig 310) encoding a very similar protein, a putative gonococcal aroB gene.
Based on the gonococcal Contig 306 sequence, primers AroB 1 and AroB2 were designed to PCR approximately lkb DNA upstream plus some of the beginning of the putative N.meningitidis aroB gene. Primers AroB3 and AroB4 were also designed to PCR
some of the end of the aroB gene and approximately 1 kb of downstream sequence.
Restriction sites were added so that the two PCR products could be cloned and joined to create a version of the aroB gene with the central portion of the gene missing. It was planned to replace the chromosomal meningococcal aroB gene with this deleted version using homologous recombination and so make an aroB mutant.
2. Cloning and sequencine of the putative menineococcal aroB gene Genomic DNA from a streptomycin resistant version of the N meningitides clone B16:B6 (Schryvers et aT, Microb. Pathog. 24, 75-87, 1998) was used for cloning the aroB
gene. PCR products AroBl-2 and AroB3-4 were generated using Taq and cloned into the pCRII vector (Invitrogen) for storage and sequencing. Resulting plasmids were labelled pCRI-2 and pCR3-4 respectively. Preliminary sequencing results (sequencing ends of PCR
products) confirmed they contained the target sequences.
3. Construction of suicide vectors for creating an aroB menin~ococcal mutant The suicide vectors are based on vector pGITS. This was derived from the pCRII
cloning vector {Invitrogen) but contains a deletion in the f3-lactamase gene for safety considerations and also a synthetic gonococcal uptake sequence cloned into the EcoRI site to guarantee uptake of the vector into Neisseriae species. In more detail, the ampicillin gene of pCRII was knocked out. A consensus DNA uptake sequence was synthesised based on Ngonorrhoea data (Burnstein et al, J. Gen. Microbiol. 134 (Pt. 3) 547-557, 1988: Stein, Can.
J. Microbiol. 37, 345-349, 1991 ). The uptake sequence was cloned into the EcoRI site of the pCRII.
The aroB deletion strategy involved two steps and used an erythromycin resistance (erythromycin R) cassette. Using a two-step process, the aroB gene could be replaced by the deleted version without leaving an antibiotic marker in the gene. The strategy did require a _28_ streptomycin-resistant N.meningitidis strain, however.
The first suicide vector contained the erythromycin R cassette sandwiched between the AroBl-2 and AroB3-4 PCR products. Firstly, AroB3-4 was legated between the KpnI and BamHI sites of pGITS to produce pGITSaroB3-4. AroB 1-2 was then legated between the KpnI and HindIII sites in pGITSaroB3-4 to make pGITSaroB O1-4. Finally, the erythromycin R cassette was inserted into the blunted KpnI site of pGITSaroB ~1-4 to produce pGITSaroB
Derm.
The second suicide vector is the same as the first, but omitting the erythromycin R
cassette. This had already been made and was pGITSaroB O1-4.
4 Interruption of the N.menin~itidis aroB gene using homologous recombination The streptomycin-resistant version of the Iv:meningitidis B16:B6 strain (B16B6strR) was transformed separately with two clones of the pGITSaroB germ vector and four erythromycin resistant clones picked and stored from each transformation (ie.
probably eight identical clones). All eight tranformants were erythromycin resistant and streptomycin sensitive. Hence, the pGITSaroB Derm cassette has almost certainly integrated into the bacterial chromosome. Kanamycin susceptibility was not tested, but would confirm the absence of the pGITS plasmid. The transformants have been cultivated on Blood Agar and GC agar plates on the assumption that both contain enough aromatic amino acids to overcome the attenuation of the predicted aro mutation. Minimum essential medium MEM
with agar (with and without Vitox) plus all the amino acids has been tested as a minimal medium, but none of the transformants grew and control strains did not grow well.
Example 2: asd mutant (Figure 4) A fragment comprising approximately 90% (1.3 kb) of the asd gene was amplified using PCR. Primers asdl and asd2 were designed by back-translation of the protein sequence based on the colon usage of N. meningitides. EcoRI sites were included at the 5' ends of the primers to facilitate cloning into the plasmid pUCl9. The resulting plasmid pASD-1 was sequenced to confirm the identity of the cloned fragment and to generate a restriction map.
Restriction sites were identified to create a deletion in the middle of the gene which also throws the latter part of the gene out of frame. The insert removed was a BcgI
fragment from positions 471-586 of the gene (where 1 is the A of the ATG start colon). This ensured complete inactivation of the gene product. A selectable marker cassette (comprising either CAT and SacRB genes which confer chloramphenicol resistance and sucrose sensitivity, or Erm and Rps 1 genes which confer erythromycin resistance and streptomycin sensitivity (Johnston, 1996, pages 37-38 in Abstracts of the 10"' International Pathogenic Neisseria Conference:
Sept. 8-13 1996, Baltimore, MD, USA; eds. Zollinger et al. )) was inserted at an NspI site of the undeleted asd gene (this occurs within the BcgI deletion site). This construct was then used to transform N.
meningitidis, with positive selection of mutants (resistance to chloramphenicol or erythromycin). Resistant colonies were then purified and transformed for a second time using the deletion construct devoid of any markers, with positive selection using either resistance to sucrose or streptomycin.
Mutants which have a mutation in the asd gene which encodes the essential cell wall enzyme -semialdehyde dehydrogenase can be identified by their requirement for diaminopimelic acid (DAP). Putative asd mutants were replica plated onto DAP-deficient and DAP-replete media. Those strains which grew on DAP-replete medium ( 100 g/ml) but not on DAP-deficient medium were asd mutants.
Example 3: ur construct (Fide 5~
For alterations in the fur gene it was essential not to have a complete knockout mutant since this may be lethal. Therefore the fur gene was placed under the control of another promoter which could be switched on or off independently of the factors (iron) which normally controls, fur expression.
Primers for the amplification of the entire fur gene were designed from the published sequence with an NdeI restriction site in the forward primer (primer furG) at the transcription start of the gene and a SalI restriction site in the reverse primer (primer furD) at the distal end of the fur gene. Primers furD and furG were used for the amplification of a 600 by fragment containing the entire fur coding sequence using PCR. The DNA fragment was polished with Pfu polymerase and cloned into the vector pCR-script (Stratagene), to give the plasmid pFUR-DG.
Primers for the amplification of a 300 by region upstream of the fur gene were designed with a BamHI restriction site in the reverse primer (primer furF), proximal to the transcription start and a San restriction site in the forward primer (primer furE), distal to the transcription start. The 300 by DNA fragment was cloned into the vector pCR-script as above to give the plasmid pFUR-EF.
Finally, two primers were designed and constructed to the IacZ promoter and repressor region (lacI) of the E. toll lac operon. The forward primer, lac 1, contained a BamHI site and the reverse primer, lac3, included the Iq mutation and an NdeI site which would regenerate the ATG transcription start when ligated to the NdeI site of the gene pFUR-DG
plasmid insert. The fragment generated using these primers was cloned into the vector pCRII
(Invitrogen), to give pLAC-13.
The Fur-EF fragment was removed from pFUR-EF by cutting with Sall and BamHl.
The Lac 13 fragment was removed from its vector with BamHI and NdeI. The Fur-DG fragment was removed from pFUR-DG by cutting with NdeI and SaII. These were sequentially ligated together to give the complete furllac construct in pUCl9. This was then sub-cloned into the pGITS suicide vector and inserted into the chromosomal location of the wild-type fur gene by allelic exchange.
In more detail, the,furllac construct was cut from the construction plasmid pUCl9-furllac using the enzyme SaIZ This was made blunt ended by filling the in 5' overhangs using klenow. The now blunted furllac fusion was cloned into the blunt EcoRV site of pGITS to give the plasmid pGITSfurllac. PGITSfurllac was transformed into the E.coli host DHSa. A 100 ml culture of DHSa (pGITSfurllac) in LB broth was grown up at 37°C to an OD6°~ = 0.7. This was used to carry out a large-scale plasmid preparation by the alkaline lysis method.
PGITSfurllac was introduced into the N meningitides strain B16:B6 as follows.
N meningitides strain B 16:B6 was grown in proteose-peptone broth at 37°C to an ODboo = 0.2.
These were pelleted by centrifugation and resuspended in an equal volume of proteose-peptone broth containing 10 mM MgCl2. To 250 p,l of bacterial suspension in a Bijou a maximum the pGITSfurllac was added to a final concentration of 1 ~,g/ml. This was incubated at 37°C for 4 hours in an atmosphere of 5% COZ in air with the lid of the culture vessel loose to allow COz entry. After this time the culture was plated onto GC agar plates and allowed to grow at 37°C in 5% C02 in air until colonies showed.
Colonies were replicated/transferred to nylon filters and colonies lysed by floating the membrane on a solution of 1% SDS. The plates were re-incubated to allow the colonies to grow up again. The DNA from the colonies on the membrane was denatured by floating on a 1N solution of NaOH and then neutralised by floating on 1 M Tris pH7Ø The filters were UV
irradiated to bind DNA to the membrane and then hybridised to a dig-labelled IacIR fragment prepared by a commercial kit (Promega). After hybridisation and extensive washing the membranes were developed using the solutions and protocol provided and N.
meningitides strains containing a IacIR fragment showed up as dark spots on the filter. The corresponding colonies were picked from the re-grown agar plates, grown up and stored.
Confirmation of the correct construct was carried out by PCR amplification of sequences from chromosomal DNA
using the fur and lac primers to confirm the presence of the fusion and its location. This will be confirmed by the Southern blots of restriction digests of chromosomal DNA.
One of the furllac strains were picked and grown for 12 hours in proteose peptone broth with varying concentrations of IPTG. Total proteins were prepared from the cultures by boiling in SDS-PAGE loading buffer (without the methylene blue dye). Lysates were dotted onto nitro-cellulose membranes and fixed in 1-% trichloro-acetic acid solution. The membranes were incubated for 1 hour with a i :1000 dilution of a rabbit polyclonal antibody to tranferrin binding proteins Tbpl and 2, in 50 mM Tris pH7.0 The membranes were washed extensively in 50 mM Tris pH7.0 and then incubated with a goat anti-rabbit secondary antibody, conjugated to alkaline phosphatase (Sigma), in 50 mM
Tris pH8.0 for 1 hour. After this time the membranes were washed in 50 mM Tris pH8.0 and developed in BCIP/NBT solution (available as tablets from Sigma). Binding of primary antibodies was seen as an intense blue/black staining in the region of the applied proteins, no antibody binding was seen as little or no colour development.
The results showed that the primary antibody to Tbp l and 2 bound more strongly to cells in the presence of IPTG than in the absence. Without IPTG there was very little binding of antibody (comparable to wild type in high iron conditions) indicating little expression of the fur/iron regulated Tbp 1 and 2. Whereas the concentration of IPTG was increased the binding of the primary antibody increased up to a level which appeared comparable to that seen with the wild type in low iron or iron free conditions. These results show that the furllac fusion strain does express its iron regulated proteins in response to IPTG. These data can be confirmed by Western blot analysis of total proteins and outer membrane proteins using various antibodies to iron regulated proteins. This could also be done for whole cells by colony blots and immunogold electron microscopy to confirm that the proteins are localised properly. Also, comparison of outer membrane profiles of iron-induced wild type IPTG induced fusion strains will show whether the profiles are similar.
Example 4: galEl mutant N. meningitides contains two chromosomal galE gene sequences, galEl and galE2 at separate loci. GalEl is complete, expressing a functional gene product, while galE2 is truncated and lacks homology over the first third of the protein. Primers galEA and galEB were designed to areas which are not conserved between galEl and galE2 to amplify a 1.5 kb fragment of galEl. A HindII site was engineered into each primer to facilitate cloning into pUCl9. After subcloning into the suicide vector pGITB (a pUC based vector with neisserial uptake sequence and lacking a BpmI site in the inactivated ampicillin gene, a selectable marker cassette (see Example 1 for alternatives) was inserted at a BpmI site (very close to the BcgI
deletion site). This construct was then used to transform N.meningitidis, and mutants identified by a chloramphenicol or erythromycin resistant phenotype. Resistant colonies were then purified and transformed for a second time using the GalEl BcgI deletion construct devoid of any markers, with positive selection using either resistance to sucrose or streptomycin.
To establish a change in LPS type, LPS is prepared from mutants and parental wild-type N.meningitidis by a proteinase K digestion of OMPs method and analysed on 15%
tricine SDS
PAGE gels. Bands are visualised by silver staining. LPS from galE mutants demonstrate greater electorphoretic mobility than their wild type parent strains.
Example 5: recA mutant.
DNA sequences of recA genes from various bacterial species were compared and primers recAl and recA2 were designed within conserved regions of the gene using the codon frequency of N. meningitides. The primers were designed with EcoRI restriction enzyme cleavage sites to facilitate cloning. The primers were used to amplify recA
from N. meningitides and the product was cloned into pUCl9. The resulting plasmid, pRECA-l, was partially sequenced to verify that the insert was from the recA gene and restriction mapped to identify useful restriction enzyme sites for the generation of the deletion derivative.
This deletion derivative, pRECA-D, was recombined into the wild type N. meningitides chromosome and the resulting strain was tested to determine its sensitivity to UV light compared to the parental strain.
UV sensitivity compared to the isogenic wild type strain can be determined by inoculating blood agar plates with parallel streaks of the wild type and the putative recA mutant.
The inoculated plates are exposed to known UV energy for increasing times. The plates are incubated at 37°C and S% COZ in air for 24 hours. UV sensitivity is shown by reduced growth of the putative mutant on plates compared to the adjacent wild-type strain. .
The strains obtained by this procedure are effectively isolated genetically and no further construction can be undertaken since they are now deficient in homologous recombination.
Example 6: DaroB. lac: fur fusion mutant The procedure of Example 3 is repeated, but this time using the attenuated N.
meningitides aroB mutant obtained by the procedure of Example 1. This provides an attenuated DaroB, laclfisr fusion mutant of N.meningitidis.
Claims (24)
1. An attenuated bacterium in which the native ferric uptake regulation (fur) gene, or a functional homologue thereof, is modified such that the expression of the fur gene product, or homologue thereof, is regulated independently of the iron concentration in the environment of the bacterium.
2. A bacterium according to claim 1 which is a gram-negative bacterium.
A bacterium according to claim 2 which is selected from the group consisting of Neisseria meningitidis, Neisseria gonorrhoeae, Helicobacter pylori, Salmonella typhi, Salmonella typhimurium, enteropathogenic E. coli (EPEC), enteroinvasive E.
coli (EIEC), enterotoxigenic E. coli (ETEC), enterohaemorrhagic E. coli (EHEC), verotoxigenic E. coli (VTEC), Vibrio cholerae, Shigella spp., Haemophilus influenzae, Bordetella pertussis and Pseudomonas aeruginosa.
coli (EIEC), enterotoxigenic E. coli (ETEC), enterohaemorrhagic E. coli (EHEC), verotoxigenic E. coli (VTEC), Vibrio cholerae, Shigella spp., Haemophilus influenzae, Bordetella pertussis and Pseudomonas aeruginosa.
4. A bacterium according to claim 3 which is selected from Neisseria meningitides and Neisseria gonorrhoeae.
5. A bacterium according to any one of the preceding claims which has been attenuated by mutation of a gene essential for the production of a metabolite or catabolite not produced by a human or animal.
6. A bacterium according to any one of the preceding claims which has been attenuated by a mutation of an aro gene and/or an asd, pur or pyr gene.
7. A bacterium according to claim 6 wherein said gene is aroA, aroB, aroC, aroD, aroL, purA, purB, purE, pyrA, pyrB or pyrE.
8. A bacterium according to any one of the preceding claims which further comprises a recA mutation.
9. A bacterium according to any one of the preceding claims which further comprises a mutation in which expression of a toxin gene has been modified or eliminated.
10. A bacterium according to any one of the preceding claims which further comprises a mutation at a site homologous to the E. coli minB locus.
11. A bacterium according to any one of the preceding claims which further comprises a mutation in a gene involved in the uptake of DNA.
12. A bacterium according to claim 11 which is N. meningitides or N.
gonorrhoeae and wherein the gene involved in the uptake of DNA is comA.
gonorrhoeae and wherein the gene involved in the uptake of DNA is comA.
13. A bacterium according to any one of the preceding claims which is N.
meningitides or N.
gonorrhoeae and which further comprises a mutation in the galE gene.
meningitides or N.
gonorrhoeae and which further comprises a mutation in the galE gene.
14. A bacterium according to claim 13 which further comprises a mutation in the opc gene to modify or eliminate expression of opc protein.
15. An N. meningitidis strain which has the genotype: aroB, lac:fur fusion, recA or aroB, galE, lac:fur fusion, recA.
16. An N. meningitidis strain which has the genotype: aroL, lac:fur fusion, recA or aroL, galE, lac:fur fusion, recA.
17. An N. meningitidis strain according to claim 15 or 16 which further comprises at least one of a minB mutation, an RTX negative phenotype, and an opc gene the expression of which has been modified or eliminated.
18. A preparation of membrane vesicles obtained from a bacterium as defined in any one of claims 1 to 17.
19. A vaccine which comprises a bacterium as defined in any one of claims 1 to 17 or a preparation as defined in to claim 18 together with a pharmaceutically acceptable diluent or carrier.
20. A vaccine according to claim 19 for use in a method of treatment of the human or animal body.
21. A method of protecting an individual against a bacterial infection which comprises administering to the individual an effective amount of a bacterium as defined in any one of claims 1 to 17 or a preparation as defined in claim 18.
22. A process for preparing a vaccine composition comprising an attenuated bacterium as defined in any one of claims 1 to 17 which process comprises:
(a) inoculating a culture vessel containing a nutrient medium suitable for growth of said bacterium;
(b) culturing said bacterium;
(c) recovering bacteria from the culture; and (d) mixing said bacteria with a pharmaceutically acceptable diluent or carrier.
(a) inoculating a culture vessel containing a nutrient medium suitable for growth of said bacterium;
(b) culturing said bacterium;
(c) recovering bacteria from the culture; and (d) mixing said bacteria with a pharmaceutically acceptable diluent or carrier.
23. A method for producing a bacterium according to claim 1 which method comprises modifying the negative fur gene, or a functional homologue thereof, of an attenuated bacterium such that expression of said fur gene of homologue is regulated independently of the iron concentration in the environment of the bacterium.
24. A method according to claim 23 wherein said bacterium has been attenuated by at least one mutation as defined in any one of claims 5 to 7.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9711964.8A GB9711964D0 (en) | 1997-06-09 | 1997-06-09 | Live attenuated vaccines |
GB9711964.8 | 1997-06-09 | ||
PCT/GB1998/001683 WO1998056901A2 (en) | 1997-06-09 | 1998-06-09 | Live attenuated vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2292900A1 true CA2292900A1 (en) | 1998-12-17 |
Family
ID=10813847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002292900A Abandoned CA2292900A1 (en) | 1997-06-09 | 1998-06-09 | Live attenuated vaccines |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0996712A2 (en) |
JP (1) | JP2002511752A (en) |
AU (1) | AU745003B2 (en) |
CA (1) | CA2292900A1 (en) |
GB (1) | GB9711964D0 (en) |
WO (1) | WO1998056901A2 (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9823978D0 (en) | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
US10967045B2 (en) | 1998-11-02 | 2021-04-06 | Secretary of State for Health and Social Care | Multicomponent meningococcal vaccine |
GB9918319D0 (en) * | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
GB9929923D0 (en) * | 1999-12-17 | 2000-02-09 | Baldwin Thomas J | Antigen preparations |
GB0011108D0 (en) * | 2000-05-08 | 2000-06-28 | Microscience Ltd | Virulence gene and protein and their use |
GB0012079D0 (en) * | 2000-05-18 | 2000-07-12 | Microscience Ltd | Virulence gene and protein, and their use |
EP1322328B1 (en) | 2000-07-27 | 2014-08-20 | Children's Hospital & Research Center at Oakland | Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
EP1345621B1 (en) * | 2000-11-16 | 2008-11-12 | Intervet International BV | Salmonella vaccine |
ATE556596T1 (en) * | 2002-04-15 | 2012-05-15 | Univ St Louis | REGULATED ATTENUATION OF LIVE VACCINES TO IMPROVE CROSS-IMMMUNITY PROTECTIVE FUNCTION |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
DK1587537T3 (en) | 2003-01-30 | 2012-07-16 | Novartis Ag | Injectable vaccines against multiple meningococ serogroups |
GB0308691D0 (en) * | 2003-04-07 | 2003-05-21 | Xenova Res Ltd | Vaccine preparations |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
RU2432962C2 (en) | 2005-01-27 | 2011-11-10 | Чилдрен'З Хоспитал Энд Рисерч Сентер Эт Окленд | Vaccines with application of vesicles based on gna 1870 of broad spectrum of action for prevention of diseases, caused by neisseria meningitidis |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
CN101951949B (en) | 2007-10-19 | 2013-10-02 | 诺华股份有限公司 | Meningococcal vaccine formulations |
CA2714292A1 (en) * | 2008-01-30 | 2009-08-06 | Jorge Barbe Garcia | Heterologous protection against pasteurella multocida provided by p. multocida fur cells and the outer-membrane protein extracts thereof |
EP3263591B1 (en) | 2008-02-21 | 2019-03-27 | GlaxoSmithKline Biologicals S.A. | Meningococcal fhbp polypeptides |
GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
WO2010070453A2 (en) | 2008-12-17 | 2010-06-24 | Novartis Ag | Meningococcal vaccines including hemoglobin receptor |
WO2010144734A1 (en) | 2009-06-10 | 2010-12-16 | Novartis Ag | Benzonaphthyridine-containing vaccines |
EP2470204B1 (en) | 2009-08-27 | 2015-12-16 | GlaxoSmithKline Biologicals SA | Hybrid polypeptides including meningococcal fhbp sequences |
WO2011024071A1 (en) | 2009-08-27 | 2011-03-03 | Novartis Ag | Adjuvant comprising aluminium, oligonucleotide and polycation |
TWI445708B (en) | 2009-09-02 | 2014-07-21 | Irm Llc | Compounds and compositions as tlr activity modulators |
ES2443952T3 (en) | 2009-09-02 | 2014-02-21 | Novartis Ag | Immunogenic compositions that include modulators of TLR activity |
AU2010302344A1 (en) | 2009-09-30 | 2012-04-26 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
MX2012004850A (en) | 2009-10-27 | 2012-05-22 | Novartis Ag | Modified meningococcal fhbp polypeptides. |
WO2011057148A1 (en) | 2009-11-05 | 2011-05-12 | Irm Llc | Compounds and compositions as tlr-7 activity modulators |
CN102762206A (en) | 2009-12-15 | 2012-10-31 | 诺华有限公司 | Homogeneous suspension of immunopotentiating compounds and uses thereof |
EP2547357A1 (en) | 2010-03-18 | 2013-01-23 | Novartis AG | Adjuvanted vaccines for serogroup b meningococcus |
EA023725B1 (en) | 2010-03-23 | 2016-07-29 | Новартис Аг | Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc. |
KR20160127104A (en) | 2014-02-28 | 2016-11-02 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Modified meningococcal fhbp polypeptides |
JP7126261B2 (en) * | 2016-02-10 | 2022-08-26 | エンジニアード アンチジェンズ インコーポレイテッド | SLAM Polynucleotides and Polypeptides and Their Use |
EP3607967A1 (en) | 2018-08-09 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Modified meningococcal fhbp polypeptides |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681761A (en) * | 1985-10-24 | 1987-07-21 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Major iron-regulated protein of Neisseria gonorrhoeae and its use as vaccine |
GB8730037D0 (en) * | 1987-12-23 | 1988-02-03 | Wellcome Found | Vaccines |
EP0659086B1 (en) * | 1992-09-04 | 1998-11-11 | The University of Saskatchewan | Novel bacterial vaccines using vaccine strains of pathogenic bacteria |
-
1997
- 1997-06-09 GB GBGB9711964.8A patent/GB9711964D0/en active Pending
-
1998
- 1998-06-09 CA CA002292900A patent/CA2292900A1/en not_active Abandoned
- 1998-06-09 AU AU80268/98A patent/AU745003B2/en not_active Ceased
- 1998-06-09 EP EP98928436A patent/EP0996712A2/en not_active Withdrawn
- 1998-06-09 JP JP50189199A patent/JP2002511752A/en active Pending
- 1998-06-09 WO PCT/GB1998/001683 patent/WO1998056901A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO1998056901A2 (en) | 1998-12-17 |
EP0996712A2 (en) | 2000-05-03 |
WO1998056901A3 (en) | 1999-03-18 |
GB9711964D0 (en) | 1997-08-06 |
AU8026898A (en) | 1998-12-30 |
AU745003B2 (en) | 2002-03-07 |
JP2002511752A (en) | 2002-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU745003B2 (en) | Live attenuated vaccines | |
ES2286905T3 (en) | PLASMID STABILIZATION SYSTEM FOR THE SUPPLY OF ANTIGENS. | |
Ramjeet et al. | Actinobacillus pleuropneumoniae vaccines: from bacterins to new insights into vaccination strategies | |
Chatfield et al. | Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine | |
US20050260223A1 (en) | Salmonella vaccine materials and methods | |
Kwaga et al. | A carAB mutant of avian pathogenic Escherichia coli serogroup O2 is attenuated and effective as a live oral vaccine against colibacillosis in turkeys | |
JPH04504204A (en) | Vaccines containing non-pathogenic phoP microorganisms | |
Homchampa et al. | Molecular analysis of the aroA gene of Pasteurella multocida and vaccine potential of a constructed aroA mutant | |
AU2001256957A1 (en) | Salmonella vaccine materials and methods | |
ES2256514T3 (en) | BACTERIAL VACCINE. | |
Adler et al. | Immunity and vaccine development in Pasteurella multocida infections | |
ES2381973T3 (en) | Live attenuated vaccine against swine pleuropneumonia | |
ES2824402T3 (en) | Attenuated vaccines against Pasteurella multocida and procedures for their manufacture and use | |
JP2002507414A (en) | Attenuated bacteria used in vaccines | |
EP1443959A1 (en) | Salmonella vaccine | |
Sirard et al. | A recombinant Bacillus anthracis strain producing the Clostridium perfringens Ib component induces protection against iota toxins | |
Garrido et al. | Heterologous protective immunization elicited in mice by Pasteurella multocida fur ompH | |
JP5547657B2 (en) | Heterologous protection against Pasteurella multocida by extracts of P. multocida fur cells and their outer membrane proteins | |
EP0358692B1 (en) | Cholera vaccines | |
MXPA99011431A (en) | Live attenuated vaccines | |
EP1640013A2 (en) | Inactivated Salmonella vaccines | |
McArthur | Rational attenuation of Bordetella bronchiseptica for vaccine purposes | |
AU2002223922A1 (en) | Salmonella vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |